<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants - Moresco, L - 2023 | Cochrane Library</title> <meta content="Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants - Moresco, L - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015462.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants - Moresco, L - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015462.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015462.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants" name="citation_title"/> <meta content="Luca Moresco&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Ospedale San Paolo" name="citation_author_institution"/> <meta content="Alice Sjögren&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Keri A Marques" name="citation_author"/> <meta content="University of Louisville" name="citation_author_institution"/> <meta content="Roger Soll" name="citation_author"/> <meta content="Larner College of Medicine at the University of Vermont" name="citation_author_institution"/> <meta content="Matteo Bruschettini" name="citation_author"/> <meta content="matteo.bruschettini@med.lu.se" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD015462.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/10/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015462.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015462.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015462.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aminophylline [therapeutic use]; Apnea [drug therapy, prevention &amp; control]; Birth Weight; *Bronchopulmonary Dysplasia [prevention &amp; control]; Caffeine [therapeutic use]; *Hearing Loss; Infant, Extremely Premature; Randomized Controlled Trials as Topic; Theophylline [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015462.pub2&amp;doi=10.1002/14651858.CD015462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZDBB8PHY";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015462\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015462\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","th","ms","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015462.pub2",title:"Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants",firstPublishedDate:"Oct 4, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015462.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015462.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015462.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015462.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015462.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015462.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015462.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015462.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015462.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015462.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3060 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015462.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#CD015462-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#CD015462-sec-0091"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#CD015462-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#CD015462-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#CD015462-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#CD015462-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#CD015462-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#CD015462-sec-0085"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/appendices#CD015462-sec-0096"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/supinfo/CD015462-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/supinfo/CD015462-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/information#CD015462-cr-0004">Luca Moresco</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/information#CD015462-cr-0005">Alice Sjögren</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/information#CD015462-cr-0006">Keri A Marques</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/information#CD015462-cr-0007">Roger Soll</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015462.pub2/information#CD015462-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Matteo Bruschettini</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/information/en#CD015462-sec-0117">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 October 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015462.pub2">https://doi.org/10.1002/14651858.CD015462.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015462-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015462-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015462-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015462-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015462-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015462-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD015462-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015462-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015462-abs-0001" lang="en"> <section id="CD015462-sec-0001"> <h3 class="title" id="CD015462-sec-0001">Background</h3> <p>Methylxanthines, including caffeine, theophylline, and aminophylline, work as stimulants of the respiratory drive, and decrease apnea of prematurity, a developmental disorder common in preterm infants. In particular, caffeine has been reported to improve important clinical outcomes, including bronchopulmonary dysplasia (BPD) and neurodevelopmental disability. However, there is uncertainty regarding the efficacy of caffeine compared to other methylxanthines. </p> </section> <section id="CD015462-sec-0002"> <h3 class="title" id="CD015462-sec-0002">Objectives</h3> <p>To assess the effects of caffeine compared to aminophylline or theophylline in preterm infants at risk of apnea, with apnea, or in the peri‐extubation phase. </p> </section> <section id="CD015462-sec-0003"> <h3 class="title" id="CD015462-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, Epistemonikos, the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), and clinicaltrials.gov in February 2023. We also checked the reference lists of relevant articles to identify additional studies. </p> </section> <section id="CD015462-sec-0004"> <h3 class="title" id="CD015462-sec-0004">Selection criteria</h3> <p><b>Studies</b> : randomized controlled trials (RCTs) and quasi‐RCTs<br/><b>Participants:</b> infants born before 34 weeks of gestation for prevention and extubation trials, and infants born before 37 weeks of gestation for treatment trials<br/><b>Intervention and comparison:</b> caffeine versus theophylline or caffeine versus aminophylline. We included all doses and duration of treatment. </p> </section> <section id="CD015462-sec-0005"> <h3 class="title" id="CD015462-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. We evaluated treatment effects using a fixed‐effect model with risk ratio (RR), risk difference (RD), and 95% confidence intervals (CI) for categorical data, and mean, standard deviation, and mean difference for continuous data. We used the GRADE approach to evaluate the certainty of evidence. </p> </section> <section id="CD015462-sec-0006"> <h3 class="title" id="CD015462-sec-0006">Main results</h3> <p>We included 22 trials enrolling 1776 preterm infants. The indication for treatment was prevention of apnea in three studies, treatment of apnea in 13 studies, and extubation management in three studies. In three studies, there were multiple indications for treatment, and in one study, the indication for treatment was unclear. In 19 included studies, the infants had a mean gestational age between 28 and 32 weeks and a mean birth weight between 1000 g and 1500 g. One study's participants had a mean gestational age of more than 32 weeks, and two studies had participants with a mean birth weight of 1500 g or more. </p> <p>Caffeine administrated for any indication may result in little to no difference in all‐cause mortality prior to hospital discharge compared to other methylxanthines (RR 1.12, 95% CI 0.68 to 1.84; RD 0.02, 95% CI ‐0.05 to 0.08; 2 studies, 396 infants; low‐certainty evidence). Only one study enrolling 79 infants reported components of the outcome moderate to severe neurodevelopmental disability at 18 to 26 months. The evidence is very uncertain about the effect of caffeine on cognitive developmental delay compared to other methylxanthines (RR 0.17, 95% CI 0.02 to 1.37; RD ‐0.12, 95% CI ‐0.24 to 0.01; 1 study, 79 infants; very low‐certainty evidence). The evidence is very uncertain about the effect of caffeine on language developmental delay compared to other methylxanthines (RR 0.76, 95% CI 0.37 to 1.58; RD ‐0.07, 95% CI ‐0.27 to 0.12; 1 study, 79 infants; very low‐certainty evidence). The evidence is very uncertain about the effect of caffeine on motor developmental delay compared to other methylxanthines (RR 0.50, 95% CI 0.13 to 1.96; RD ‐0.07, 95% CI ‐0.21 to 0.07; 1 study, 79 infants; very low‐certainty evidence). The evidence is very uncertain about the effect of caffeine on visual and hearing impairment compared to other methylxanthines. At 24 months of age, visual impairment was seen in 8 out of 11 infants and 10 out of 11 infants in the caffeine and other methylxanthines groups, respectively. Hearing impairment was seen in 2 out of 5 infants and 1 out of 1 infant in the caffeine and other methylxanthines groups, respectively. No studies reported the outcomes cerebral palsy, gross motor disability, and mental development. Compared to other methylxanthines, caffeine may result in little to no difference in BPD/chronic lung disease, defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age (RR 1.40, 95% CI 0.92 to 2.11; RD 0.04, 95% CI ‐0.01 to 0.09; 3 studies, 481 infants; low‐certainty evidence). The evidence is very uncertain about the effect of caffeine on side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines compared to other methylxanthines (RR 0.17, 95% CI 0.02 to 1.32; RD ‐0.29, 95% CI ‐0.57 to ‐0.02; 1 study, 30 infants; very low‐certainty evidence). Caffeine may result in little to no difference in duration of hospital stay compared to other methylxanthines (median (interquartile range): caffeine 43 days (27.5 to 61.5); other methylxanthines 39 days (28 to 55)). No studies reported the outcome seizures. </p> </section> <section id="CD015462-sec-0007"> <h3 class="title" id="CD015462-sec-0007">Authors' conclusions</h3> <p>Although caffeine has been shown to improve important clinical outcomes, in the few studies that compared caffeine to other methylxanthines, there might be little to no difference in mortality, bronchopulmonary dysplasia, and duration of hospital stay. The evidence is very uncertain about the effect of caffeine compared to other methylxanthines on long‐term development and side effects. </p> <p>Although caffeine or other methylxanthines are widely used in preterm infants, there is little direct evidence to support the choice of which methylxanthine to use. More research is needed, especially on extremely preterm infants born before 28 weeks of gestation. Data from four ongoing studies might provide more evidence on the effects of caffeine or other methylxanthines. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015462-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015462-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015462-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015462-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015462-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015462-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015462-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD015462-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD015462-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015462-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015462-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015462-abs-0002" lang="en"> <h3>Which common stimulant medicine is best for premature babies whose breathing pauses during sleep (apnea)? </h3> <p><b>Key messages</b> </p> <p>• Caffeine and other similar substances belong to a group of stimulants called methylxanthines. They are often used to prevent and treat apnea – when breathing repeatedly stops and starts – in newborn babies. </p> <p>• Caffeine may result in little to no difference in the frequency of death in babies born too early compared to other methylxanthines. </p> <p>• More studies are needed, especially in babies born extremely early, since these babies tend to be the most poorly. </p> <p><b>What is apnea of prematurity?</b> </p> <p>Apnea of prematurity is whenbabies born too early (preterm babies) stop breathing for 20 seconds or longer during sleep. More than half of all preterm babies have apnea.Preterm babies, especially those born before 28 weeks in the womb (gestation), have a higher risk of death, lung disease, and brain impairment than those born at or near their due date. Some of these babies develop intellectual disabilities, blindness, or deafness. </p> <p><b>How is apnea in preterm babies treated?</b> </p> <p>Apnea in preterm babies is commonly treated with methylxanthines – substances found in high concentrations in tea, coffee, and chocolate. Three types of methylxanthines are caffeine, aminophylline, and theophylline. They act as mild stimulants to speed up the body’s systems and make breathing easier. When given to preterm babies, the aim is to improve their breathing and to reduce apnea episodes and the need for breathing machines (mechanical ventilation). </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if caffeine is better than aminophylline or theophylline in preterm babies for: </p> <p>• preventing death prior to hospital discharge;</p> <p>• improving long‐term development at age 18 to 24 months of age.</p> <p>We also wanted to find out if these medicines were associated with any unwanted effects.</p> <p><b>What did we do?</b> </p> <p>We searched for studies that looked at caffeine compared with aminophylline or theophylline in preterm babies. We compared and summarized the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We included 22 studies in our review, with a total of 1776 preterm newborns. Three studies evaluated the use of methylxanthines for apnea prevention; 13 studies evaluated their use for apnea treatment; two for extubation management (that is, removing the tube placed in the windpipe to help a baby breath). In three studies, there were different reasons to treat the babies with methylxanthines. Almost all studies included babies that were born, on average, after 28 to 32 weeks of gestation and with an average weight at birth between 1000 and 1500 grams. No studies had an average length of gestation of less than 28 weeks or an average birth weight of less than 1000 grams. In one study, the babies had an average length of gestation of more than 32 weeks. In two studies, the average birth weight was greater than 1500 grams. </p> <p>• For the frequency of death, we found that there may be little to no difference between the use of caffeine compared to other methylxanthines. <br/>• When looking at abilities associated with the development of the brain, it is unclear which is the better option: caffeine or other methylxanthines.<br/>• Some babies with apnea episodes develop long‐lasting lung disease. Our review indicates that there may be little to no difference between the use of caffeine and other methylxanthines for long‐lasting lung disease. <br/>• It is unclear if caffeine results in more unwanted effects compared to other methylxanthines. <br/>• We found that there may be no difference in how long the babies and their families need to stay in the hospital with the use of caffeine compared to other methylxanthines. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence is limited because the number of babies studied for each outcome we were interested in was small. All babies were randomly placed into groups receiving either caffeine or another methylxanthine (aminophylline or theophylline). However, in many studies, it is possible that staff working with the babies were aware of which treatment the babies were getting. Furthermore, the evidence did not cover all the outcomes we were interested in. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to February 2023.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015462-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015462-sec-0091"></div> <h3 class="title" id="CD015462-sec-0092">Implications for practice</h3> <section id="CD015462-sec-0092"> <p>Although caffeine has been shown to improve important clinical outcomes for preterm infants with or at risk of apnea, in the few studies that compared caffeine to other methylxanthines, there might be little to no difference in mortality, bronchopulmonary dysplasia, and duration of hospital stay. The evidence is very uncertain about the effect of caffeine compared to other methylxanthines on long‐term development and side effects. </p> <p>Although caffeine or other methylxanthines are widely used in preterm infants, there is little direct evidence to support the choice of which methylxanthine to use. Caffeine has the main advantages of single daily administration and reassuring long‐term safety data, whereas aminophylline and theophylline are less expensive and their use might be considered acceptable in lower‐income countries. </p> </section> <h3 class="title" id="CD015462-sec-0093">Implications for research</h3> <section id="CD015462-sec-0093"> <p>Future studies should investigate long‐term neurodevelopmental outcomes for caffeine compared to other methylxanthines. Research is also needed to explore short‐term outcomes, such as the frequency of adverse effects. It would be preferable to conduct studies with infants born at less than 28 weeks of gestation since these infants are at highest risk of developing apnea of prematurity. Data from the four ongoing studies might provide more evidence on the effects of caffeine or other methylxanthines. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015462-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015462-sec-0008"></div> <div class="table" id="CD015462-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Caffeine compared to other methylxanthines for the prevention and treatment of apnea in preterm infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Caffeine compared to other methylxanthines for the prevention and treatment of apnea in preterm infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> preterm infants <br/><b>Setting:</b> neonatal intensive care units<br/><b>Intervention:</b> caffeine <br/><b>Comparison:</b> other methylxanthines </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Without caffeine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With caffeine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality prior to hospital discharge</b> <br/><b>№ of participants:</b> 396<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/>(0.68 to 1.84) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caffeine may result in little to no difference in all‐cause mortality prior to hospital discharge compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.1%<br/>(8.6 to 23.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5% more<br/>(4 fewer to 10.6 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate to severe neurodevelopmental disability at 18 to 26 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>No studies reported this composite outcome. Components of this outcome are reported below. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a) Cerebral palsy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>b) Gross motor disability defined as ≥ level 2 according to the GMFCS</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>c) Developmental delay more than two SDs below population mean on a standardized test of development: cognitive delay </p> <p>№ of participants: 79<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.17<br/>(0.02 to 1.37) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of caffeine on cognitive developmental delay compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4% (0.3 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5% fewer (13.6 fewer to 5.1 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>c) Developmental delay more than two SDs below population mean on a standardized test of development: language delay </p> <p>№ of participants: 79<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.76 (0.37 to 1.58)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of caffeine on language developmental delay compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.2% (11.3 to 48.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.4% fewer (28.3 fewer to 8.7 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>c) Developmental delay more than two SDs below population mean on a standardized test of development: motor delay </p> <p>№ of participants: 79<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.50 (0.13 to 1.96)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of caffeine on motor developmental delay compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9% (1.8 to 27.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7% fewer (12.1 fewer to 13.3 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d) Mental development IQ &gt; 2 SD below the mean</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>e) Visual impairment (vision &lt; 6/60 in both eyes)</p> <p>№ of participants: 21<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>This outcome was reported only for those infants with ROP diagnosis at discharge. Visual impairment was seen in 8 out of 11 and 10 out of 11 infants in the caffeine and other methylxanthines groups, respectively. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of caffeine on visual impairment compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>f) Hearing impairment (requiring amplification)</p> <p>№ of participants: 6<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>This outcome was reported only for those infants with abnormal hearing screening prior to discharge using ABR and OAE. Hearing impairment was seen in 2 out of 5 infants and 1 out of 1 infant in the caffeine and other methylxanthines groups, respectively. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of caffeine on hearing impairment compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Bronchopulmonary dysplasia/chronic lung disease: defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age</b> <br/><b>№ of participants:</b> 481<br/>(3 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/>(0.92 to 2.11) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caffeine may result in little to no difference in bronchopulmonary dysplasia/chronic lung disease (defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age) compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.5%<br/>(8.9 to 20.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9% more<br/>(0.8 fewer to 10.7 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines</b> <br/><b>№ of participants:</b> 30<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.17<br/>(0.02 to 1.32) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of caffeine on side effects ((tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines) compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1%<br/>(0.7 to 47.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.6% fewer<br/>(35 fewer to 11.4 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of hospital stay (days)</b> </p> <p><b>№ of participants:</b> 240 </p> <p>(1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>One study reported this outcome with median and IQR and therefore could not be pooled in the meta‐analysis: caffeine 43 days (IQR 27.5 to 61.5); other methylxanthines: 39 (IQR 28 to 55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caffeine may result in little to no difference in duration of hospital stay compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizures (clinically diagnosed)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>ABR:</b> auditory brainstem evoked response; <b>CI:</b> confidence interval; <b>GMFCS</b> : Gross Motor Function Classification System; <b>IQ:</b> intelligence quotient; <b>IQR</b> : interquartile range; <b>OAE</b> : otoacoustic emission; <b>RCT:</b> randomized controlled trial; <b>ROP</b> : retinopathy of prematurity; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision: very wide CIs<br/><sup>b</sup>Downgraded one level for serious study limitations: multiple domains of the risk of bias unclear or high<br/><sup>c</sup>Downgraded two levels for very serious imprecision: one study with wide CIs<br/><sup>d</sup>Downgraded two levels for very serious imprecision: one study with very few infants and events<br/><sup>e</sup>Downgraded one level for serious imprecision: three studies, wide CIs<br/><sup>f</sup>Downgraded three levels for extremely serious imprecision: very wide CI; few infants and events<br/><sup>g</sup>Downgraded two levels for very serious imprecision: one study with wide interquartile ranges </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015462-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015462-sec-0009"></div> <section id="CD015462-sec-0010"> <h3 class="title" id="CD015462-sec-0010">Description of the condition</h3> <p>Apnea of prematurity is a developmental disorder in preterm infants that is a consequence of immature respiratory control (<a href="./references#CD015462-bbs2-0062" title="EichenwaldEC , Committee on Fetus and Newborn, American Academy of Pediatrics. Apnea of prematurity. Pediatrics2016;137(1):1-7. [PMID: 26628729]">Eichenwald 2016</a>; <a href="./references#CD015462-bbs2-0090" title="MartinR . Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity; November 2022. www.uptodate.com/contents/pathogenesis-clinical-manifestations-and-diagnosis-of-apnea-of-prematurity (accessed prior to 12 March 2023).">Martin 2023</a>). It occurs more frequently with decreasing gestational age (<a href="./references#CD015462-bbs2-0068" title="Henderson-SmartDJ . The effect of gestational age on the incidence and duration of recurrent apnoea in newborn babies. Australian Paediatric Journal1981;17(4):273-6. [DOI: 10.1111/j.1440-1754.1981.tb01957.x] [PMID: 7347216]">Henderson‐Smart 1981</a>; <a href="./references#CD015462-bbs2-0090" title="MartinR . Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity; November 2022. www.uptodate.com/contents/pathogenesis-clinical-manifestations-and-diagnosis-of-apnea-of-prematurity (accessed prior to 12 March 2023).">Martin 2023</a>). The incidence of apnea of prematurity is estimated at over 50% in all preterm newborns, and nearly 100% in infants with a birth weight of less than 1000 grams (<a href="./references#CD015462-bbs2-0041" title="AldenER , MandelkornT , WoodrumDE , WennbergRP , ParksCR , HodsonWA . Morbidity and mortality of infants weighing less than 1,000 grams in an intensive care nursery. Pediatrics1972;50(1):40-9. [PMID: 4556739]">Alden 1972</a>; <a href="./references#CD015462-bbs2-0046" title="BarringtonK , FinerN . The natural history of the appearance of apnea of prematurity. Pediatric Research1991;29(4 Pt 1):372-5. [DOI: 10.1038/pr.1991.72500] [PMID: 1852531]">Barrington 1991</a>; <a href="./references#CD015462-bbs2-0054" title="DailyWJ , KlausM , MeyerHB . Apnea in premature infants: monitoring, incidence, heart rate changes, and an effect of environmental temperature. Pediatrics1969;43(4):510-8. [PMID: 5777065]">Daily 1969</a>; <a href="./references#CD015462-bbs2-0090" title="MartinR . Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity; November 2022. www.uptodate.com/contents/pathogenesis-clinical-manifestations-and-diagnosis-of-apnea-of-prematurity (accessed prior to 12 March 2023).">Martin 2023</a>). Clinically significant episodes of apnea are considered to be those lasting longer than 20 seconds or when shorter episodes are characterized by hypoxemia, bradycardia, or both (<a href="./references#CD015462-bbs2-0062" title="EichenwaldEC , Committee on Fetus and Newborn, American Academy of Pediatrics. Apnea of prematurity. Pediatrics2016;137(1):1-7. [PMID: 26628729]">Eichenwald 2016</a>; <a href="./references#CD015462-bbs2-0090" title="MartinR . Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity; November 2022. www.uptodate.com/contents/pathogenesis-clinical-manifestations-and-diagnosis-of-apnea-of-prematurity (accessed prior to 12 March 2023).">Martin 2023</a>). </p> <p>Central apnea – the main type of apnea of prematurity in preterm newborns – is defined as the absence of inspiratory efforts and is caused by immature respiratory control (<a href="./references#CD015462-bbs2-0090" title="MartinR . Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity; November 2022. www.uptodate.com/contents/pathogenesis-clinical-manifestations-and-diagnosis-of-apnea-of-prematurity (accessed prior to 12 March 2023).">Martin 2023</a>). The neural control of breathing is complex: it comprises a brainstem central pattern generator regulated by central and peripheral feedback mechanisms (<a href="./references#CD015462-bbs2-0042" title="AlheidGF , McCrimmonDR . The chemical neuroanatomy of breathing. Respiratory Physiology &amp; Neurobiology2008;164(1-2):3-11. [DOI: 10.1016/j.resp.2008.07.014] [PMID: 18706532]">Alheid 2008</a>; <a href="./references#CD015462-bbs2-0092" title="McCrimmonDR , MitchellGS , AlheidGF . Overview: the neurochemistry of respiratory control. Respiratory Physiology &amp; Neurobiology2008;164(1-2):1-2. [DOI: 10.1016/j.resp.2008.07.021] [PMID: 18721910]">McCrimmon 2008</a>). Prolonged apnea lasting at least one minute can lead to hypoxemia, and is related to disability and late death (i.e. death after 36 weeks’ postmenstrual age) in preterm infants (<a href="./references#CD015462-bbs2-0099" title="PoetsCF , RobertsRS , SchmidtB , WhyteRK , AsztalosEV , BaderD , et al. Association between intermittent hypoxemia or bradycardia and late death or disability in extremely preterm infants. JAMA2015;314(6):595-603. [DOI: 10.1001/jama.2015.8841] [PMID: 26262797]">Poets 2015</a>). Moreover, apnea and intermittent hypoxic episodes increase an infant's risk of developing chronic conditions, such as retinopathy of prematurity (<a href="./references#CD015462-bbs2-0059" title="Di FioreJM , BloomJN , OrgeF , SchuttA , SchluchterM , CheruvuVK , et al. A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity. Journal of Pediatrics2010;157(1):69-73. [DOI: 10.1016/j.jpeds.2010.01.046] [PMID: 20304417]">Di Fiore 2010</a>). Apnea is also associated with adverse neurodevelopmental outcomes (<a href="./references#CD015462-bbs2-0077" title="JanvierA , KhairyM , KokkotisA , CormierC , MessmerD , BarringtonKJ . Apnea is associated with neurodevelopmental impairment in very low birth weight infants. Journal of Perinatology2004;24(12):763-8. [DOI: 10.1038/sj.jp.7211182] [PMID: 15329741]">Janvier 2004</a>); however, this association is not seen in all studies (<a href="./references#CD015462-bbs2-0081" title="KoonsAH , MojicaN , JadejaN , OstfeldB , HiattM , HegyiT . Neurodevelopmental outcome of infants with apnea of infancy. American Journal of Perinatology1993;10(3):208-11. [DOI: 10.1055/s-2007-994719] [PMID: 7686008]">Koons 1993</a>). </p> </section> <section id="CD015462-sec-0011"> <h3 class="title" id="CD015462-sec-0011">Description of the intervention</h3> <p>Methylxanthines are alkaloids, found in high concentrations in tea, coffee, and chocolate, acting as a mild stimulant and bronchodilator. The pharmacologic effects of methylxanthines with regard to apnea of prematurity include enhanced stimulation of the respiratory drive (<a href="./references#CD015462-bbs2-0044" title="ArandaJV , TurmenT , DavisJ , TrippenbachT , GrondinD , ZinmanR , et al. Effect of caffeine on control of breathing in infantile apnea. Journal of Pediatrics1983;103(6):975-8. [DOI: 10.1016/s0022-3476(83)80735-5] [PMID: 6644439]">Aranda 1983</a>), along with increased diaphragmatic activity (<a href="./references#CD015462-bbs2-0082" title="KraaijengaJV , HuttenGJ , deJonghFH , vanKaamAH . The effect of caffeine on diaphragmatic activity and tidal volume in preterm infants. Journal of Pediatrics2015;167(1):70-75. [DOI: 10.1016/j.jpeds.2015.04.040] [PMID: 25982138]">Kraaijenga 2015</a>). Methylxanthines may help to prevent or treat apnea of prematurity, and thus help an infant to avoid mechanical ventilation (or reduce time spent on a ventilator), chronic lung disease, and neurodevelopmental impairment (<a href="./references#CD015462-bbs2-0056" title="DavisPG , SchmidtB , RobertsRS , DoyleLW , AsztalosE , HaslamR , et al, Caffeine for Apnea of Prematurity Trial Group. Caffeine for apnea of prematurity trial: benefits may vary in subgroups. Journal of Pediatrics2010;156(3):382-7. [DOI: 10.1016/j.jpeds.2009.09.069] [PMID: 19926098]">Davis 2010</a>; <a href="./references#CD015462-bbs2-0103" title="SchmidtB , RobertsRS , DavisP , DoyleLW , BarringtonKJ , OhlssonA , et al, Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. New England Journal of Medicine2006;354(20):2112-21. [DOI: 10.1056/NEJMoa054065] [PMID: 16707748]">Schmidt 2006</a>; <a href="./references#CD015462-bbs2-0104" title="SchmidtB , RobertsRS , DavisP , DoyleLW , BarringtonKJ , OhlssonA , et al, Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. New England Journal of Medicine2007;8(357):1893-902. [DOI: 10.1056/NEJMoa073679] [PMID: 17989382]">Schmidt 2007</a>). </p> <p>Since the 1970s, methylxanthines – including caffeine, theophylline, and aminophylline – have been the main pharmacologic intervention for treating apnea of prematurity (<a href="./references#CD015462-bbs2-0083" title="KuzemkoJA , PaalaJ . Apnoeic attacks in the newborn treated with aminophylline. Archives of Disease in Childhood1973;48(5):404-6. [DOI: 10.1136/adc.48.5.404] [PMID: 4703073]">Kuzemko 1973</a>; <a href="./references#CD015462-bbs2-0087" title="LuceyJF . The xanthine treatment of apnea of prematurity. Pediatrics1975;55(5):584-86. [PMID: 1128983]">Lucey 1975</a>). </p> <p> <ul id="CD015462-list-0001"> <li> <p>Caffeine is most commonly administered in the form of caffeine citrate. The standard dosage for intravenous and oral administration involves a loading dose of 20 mg/kg followed by a maintenance dose of 5 to 10 mg/kg/day (<a href="./references#CD015462-bbs2-0102" title="RheinLM , DobsonNR , DarnallRA , CorwinMJ , HeerenTC , PoetsCF , et al, Caffeine Pilot Study Group. Effects of caffeine on intermittent hypoxia in infants born prematurely: a randomized clinical trial. JAMA Pediatrics2014;168(3):250-7. [DOI: 10.1001/jamapediatrics.2013.4371] [PMID: 24445955]">Rhein 2014</a>). Caffeine base, used in some regions, is administered at half the dose of caffeine citrate. </p> </li> <li> <p>Theophylline is administered via oral or intravenous route, at an initial dosage of 6 to 8 mg/kg, then 1.5 to 2.5 mg/kg every 8 to 12 hours (<a href="./references#CD015462-bbs2-0100" title="ReeseJ , PrenticeG , YuVY . Dose conversion from aminophylline to theophylline in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1994;71(1):F51-2. [DOI: 10.1136/fn.71.1.f51] [PMID: 8092873]">Reese 1994</a>; <a href="./references#CD015462-bbs2-0107" title="ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2019</a>). </p> </li> <li> <p>Aminophylline is a combination of theophylline and ethylenediamine, which confers greater solubility in water. It is administered, intravenously or orally, at the same dose as theophylline (<a href="./references#CD015462-bbs2-0080" title="KondoT , KondoY , OritaY , MitaraiF , IshitsukaY , IrikuraM , et al. Predictive factors for efficacy and safety of prophylactic theophylline for extubation in infants with apnea of prematurity. PloS One2016;11(7):e0157198. [DOI: 10.1371/journal.pone.0157198] [PMID: 27388444]">Kondo 2016</a>). </p> </li> </ul> </p> <p>The original trials of methylxanthines utilized theophylline or aminophylline and mostly addressed short‐term outcomes. All three of these methylxanthine preparations have been demonstrated to reduce apneic events in treated infants (<a href="./references#CD015462-bbs2-0088" title="MarquesK , BruschettiniM , RoehrCC , DavisPG , FianderM , SollR . Methylxanthine for the prevention and treatment of apnea in preterm infants. Cochrane Database of Systematic Reviews2023, Issue [in press]. Art. No: CD013830. [DOI: 10.1002/14651858.CD013830.pub2]">Marques 2023</a>). More recent trials have utilized caffeine and have shown promising results regarding lung injury (bronchopulmonary dysplasia (BPD)), cerebral palsy, and developmental outcome (<a href="./references#CD015462-bbs2-0103" title="SchmidtB , RobertsRS , DavisP , DoyleLW , BarringtonKJ , OhlssonA , et al, Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. New England Journal of Medicine2006;354(20):2112-21. [DOI: 10.1056/NEJMoa054065] [PMID: 16707748]">Schmidt 2006</a>; <a href="./references#CD015462-bbs2-0104" title="SchmidtB , RobertsRS , DavisP , DoyleLW , BarringtonKJ , OhlssonA , et al, Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. New England Journal of Medicine2007;8(357):1893-902. [DOI: 10.1056/NEJMoa073679] [PMID: 17989382]">Schmidt 2007</a>). Evidence is less clear on the longer‐term effects of the other methylxanthines. </p> <section id="CD015462-sec-0012"> <h4 class="title">Treatment indications</h4> <p>In preterm infants, methylxanthines have been used for three indications: prophylactic treatment for infants considered to be at high risk of having apnea of prematurity (prevention); treatment of infants having apneic episodes; and treatment of infants to facilitate extubation from assisted ventilation (peri‐extubation). In fact, the largest trial of methylxanthines, the Caffeine for Apnea of Prematurity (CAP) trial, enrolled infants with any of the three indications (<a href="./references#CD015462-bbs2-0103" title="SchmidtB , RobertsRS , DavisP , DoyleLW , BarringtonKJ , OhlssonA , et al, Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. New England Journal of Medicine2006;354(20):2112-21. [DOI: 10.1056/NEJMoa054065] [PMID: 16707748]">Schmidt 2006</a>). All three approaches have proven to be successful in reducing apnea of prematurity (<a href="./references#CD015462-bbs2-0056" title="DavisPG , SchmidtB , RobertsRS , DoyleLW , AsztalosE , HaslamR , et al, Caffeine for Apnea of Prematurity Trial Group. Caffeine for apnea of prematurity trial: benefits may vary in subgroups. Journal of Pediatrics2010;156(3):382-7. [DOI: 10.1016/j.jpeds.2009.09.069] [PMID: 19926098]">Davis 2010</a>). However, there is little evidence from trials of aminophylline or theophylline regarding important longer‐term outcomes, such as cerebral palsy or neurodevelopment, and few trials that directly compare these treatment approaches to each other (<a href="./references#CD015462-bbs2-0088" title="MarquesK , BruschettiniM , RoehrCC , DavisPG , FianderM , SollR . Methylxanthine for the prevention and treatment of apnea in preterm infants. Cochrane Database of Systematic Reviews2023, Issue [in press]. Art. No: CD013830. [DOI: 10.1002/14651858.CD013830.pub2]">Marques 2023</a>). </p> </section> <section id="CD015462-sec-0013"> <h4 class="title">Potential harms and adverse effects</h4> <p>Methylxanthine toxicity may occur due to reduced renal clearance in preterm infants, leading to a longer half‐life, causing tachycardia (increased heart rate), seizures, and gastrointestinal effects (<a href="./references#CD015462-bbs2-0040" title="al-OmranA , al-AlaiyanS . Theophylline concentration following equal doses of intravenous aminophylline and oral theophylline in preterm infants. American Journal of Perinatology1997;14(3):147-9. [DOI: 10.1055/s-2007-994116] [PMID: 9259917]">al‐Omran 1997</a>). Methylxanthines might cause jitteriness, feeding intolerance, tremors (<a href="./references#CD015462-bbs2-0075" title="HowellJ , ClozelM , Aranda JV . Adverse effects of caffeine and theophylline in the newborn infant. Seminars in Perinatology1981;5(4):359-69. [PMID: 7302612]">Howell 1981</a>), reduced weight gain (<a href="./references#CD015462-bbs2-0103" title="SchmidtB , RobertsRS , DavisP , DoyleLW , BarringtonKJ , OhlssonA , et al, Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. New England Journal of Medicine2006;354(20):2112-21. [DOI: 10.1056/NEJMoa054065] [PMID: 16707748]">Schmidt 2006</a>), necrotizing enterocolitis (NEC) (<a href="./references#CD015462-bbs2-0064" title="ErenbergA , LeffRD , HaackDG , MosdellKW , HicksGM , WynneBA . Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study. Pharmacotherapy2000;20(6):644-52. [DOI: 10.1592/phco.20.7.644.35167] [PMID: 10853619]">Erenberg 2000</a>), and osteopenia (<a href="./references#CD015462-bbs2-0043" title="AliE , Rockman-GreenbergC , MoffattM , NarveyM , ReedM , JiangD . Caffeine is a risk factor for osteopenia of prematurity in preterm infants: a cohort study. BMC Pediatrics2018;18(1):9. [DOI: 10.1186/s12887-017-0978-6] [PMID: 29357829]">Ali 2018</a>). For these reasons, aminophylline and theophylline are routinely measured in plasma to avoid high concentrations (&lt; 12 micrograms/mL) (<a href="./references#CD015462-bbs2-0074" title="HochwaldC , KennedyK , ChangJ , MoyaF . A randomized, controlled, double-blind trial comparing two loading doses of aminophylline. Journal of Perinatology2002;22(4):275-8. [PMID: 12032788]">Hochwald 2002</a>). </p> <p>Less toxicity is seen with caffeine. Caffeine has more reliable enteral absorption and seems to be associated with fewer and milder adverse effects than aminophylline and theophylline (<a href="./references#CD015462-bbs2-0050" title="BlanchardPW , ArandaJV . Pharmacotherapy of respiratory control disorders. In: BeckermanRC , BrouilletteRT , HuntCE , editors(s). Respiratory Control Disorders in Infants and Children. Baltimore (MD): Williams &amp; Wilkins, 1992:352-70.">Blanchard 1992</a>; <a href="./references#CD015462-bbs2-0105" title="SchoenK , YuT , StockmannC , SpigarelliMG , SherwinCM . Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. Paediatric Drugs2014;16(2):169-77. [DOI: 10.1007/s40272-013-0063-z] [PMID: 24399614]">Schoen 2014</a>). Caffeine has an extended half‐life in neonates, exceeding 100 hours in preterm infants (<a href="./references#CD015462-bbs2-0053" title="CharlesBG , TownsendSR , SteerPA , FlenadyVJ , GrayPH , ShearmanA . Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Therapeutic Drug Monitoring2008;30(6):709-16. [DOI: 10.1097/FTD.0b013e3181898b6f] [PMID: 19057373]">Charles 2008</a>). Serum caffeine levels can be measured with micro methods (such as dried blood spot), but are not routinely measured because caffeine has a wide therapeutic index: doses that are two‐ or threefold higher than the standard dose (described above) have been used with no harms (<a href="./references#CD015462-bbs2-0051" title="BruschettiniM , BarcoS , RomantsikO , RissoF , GennaiI , ChineaB , et al. DBS-LC-MS/MS assay for caffeine: validation and neonatal application. Bioanalysis2016;8(18):1893-902. [DOI: 10.4155/bio-2016-0127] [PMID: 27532249]">Bruschettini 2016</a>). <a href="./references#CD015462-bbs2-0093" title="NatarajanG , BoticaML , ThomasR , ArandaJV . Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise?Pediatrics2007;119(5):936-40. [DOI: 10.1542/peds.2006-2986] [PMID: 17473094]">Natarajan 2007</a> showed that neonates treated with a median dose of caffeine citrate of 5 mg/kg had target plasma caffeine levels of 5 to 20 mg/dL. The American Academy of Pediatrics Committee on Fetus and Newborn do not recommend routine monitoring of plasma levels of caffeine (<a href="./references#CD015462-bbs2-0062" title="EichenwaldEC , Committee on Fetus and Newborn, American Academy of Pediatrics. Apnea of prematurity. Pediatrics2016;137(1):1-7. [PMID: 26628729]">Eichenwald 2016</a>). </p> </section> <section id="CD015462-sec-0014"> <h4 class="title">Use in low‐ and middle‐income settings</h4> <p>Although more is known about the longer‐term benefits of caffeine (<a href="./references#CD015462-bbs2-0088" title="MarquesK , BruschettiniM , RoehrCC , DavisPG , FianderM , SollR . Methylxanthine for the prevention and treatment of apnea in preterm infants. Cochrane Database of Systematic Reviews2023, Issue [in press]. Art. No: CD013830. [DOI: 10.1002/14651858.CD013830.pub2]">Marques 2023</a>), aminophylline and theophylline are used in many lower‐income countries because caffeine is more expensive, more difficult to manufacture, and its shortages may be frequent (<a href="./references#CD015462-bbs2-0107" title="ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2019</a>; <a href="./references#CD015462-bbs2-0110" title="YeC , MiaoC , YuL , DongZ , ZhangJ , MaoY , et al. Factors affecting the efficacy and safety of aminophylline in treatment of apnea of prematurity in neonatal intensive care unit. Pediatrics and Neonatology2019;60(1):43-9. [DOI: 0.1016/j.pedneo.2018.03.008] [PMID: 29673564]">Ye 2019</a>). One observational study reporting sensory neural outcomes at 14 years of age in very low birth weight preterm infants suggested that infants exposed to theophylline experienced higher rates of cerebral palsy than those not exposed but had higher scores on psychometric testing (<a href="./references#CD015462-bbs2-0055" title="DavisPG , DoyleLW , RickardsAL , KellyEA , FordGW , DavisNM , et al. Methylxanthines and sensorineural outcome at 14 years in children &lt; 1501 g birthweight. Journal of Paediatrics and Child Health2000;36(1):47-50. [DOI: 10.1046/j.1440-1754.2000.00446.x] [PMID: 10723691]">Davis 2000</a>). </p> </section> </section> <section id="CD015462-sec-0015"> <h3 class="title" id="CD015462-sec-0015">How the intervention might work</h3> <p>Methylxanthines involve multiple mechanisms of actions in the central and peripheral neural pathways controlling breathing. They work as respiratory stimulants at the level of the brainstem through antagonism of adenosine receptors (A1 and A2): in this way, they stimulate breathing and reduce suppression of breathing in the medullary respiratory control regions (<a href="./references#CD015462-bbs2-0091" title="MayerCA , HaxhiuMA , MartinRJ , WilsonCG . Adenosine A2A receptors mediate GABAergic inhibition of respiration in immature rats. Journal of Applied Physiology2006;100(1):91-7. [DOI: 10.1152/japplphysiol.00459.2005] [PMID: 16141383]">Mayer 2006</a>). Respiratory drive, the intensity of the output of respiratory centers, is increased by the inhibitory activity of A1 and A2 receptors on release of γ‐(gamma) Aminobutyric acid (GABA) (<a href="./references#CD015462-bbs2-0070" title="HerleniusE , AdenU , TangLQ , LagercrantzH . Perinatal respiratory control and its modulation by adenosine and caffeine in the rat. Pediatric Research2002;51(1):4-12. [DOI: 10.1203/00006450-200201000-00004] [PMID: 11756633]">Herlenius 2002</a>; <a href="./references#CD015462-bbs2-0079" title="JonkmanAH , De VriesJ , HeunksLM . Physiology of the respiratory drive in ICU patients: implications for diagnosis and treatment. Critical Care2020;24(1):104. [DOI: 10.1186/s13054-020-2776-z] [PMID: 32204710]">Jonkman 2020</a>). Moreover, a relatively high concentration of methylxanthines causes the release of intracellular calcium and antagonizes the GABA's receptor; that is, GABA<sub>A</sub> (inhibition of phosphodiesterase) (<a href="./references#CD015462-bbs2-0045" title="AtikA , HardingR , De MatteoR , Kondos-DevcicD , CheongJ , DoyleLW , et al. Caffeine for apnea of prematurity: effects on the developing brain. Neurotoxicology2017;58:94-102. [DOI: 10.1016/ j.neuro.2016.11.012] [PMID: 27899304]">Atik 2017</a>). Finally, methylxanthines increase brain stem sensitivity to carbon dioxide, which results in an increase of diaphragmatic function, with higher tidal volume and minute ventilation (<a href="./references#CD015462-bbs2-0060" title="DobsonNR , HuntCE . Caffeine: an evidence-based success story in VLBW pharmacotherapy. Pediatric Research2018;84(3):333-40. [DOI: 10.1038/s41390-018-0089-6] [PMID: 29983414]">Dobson 2018</a>; <a href="./references#CD015462-bbs2-0082" title="KraaijengaJV , HuttenGJ , deJonghFH , vanKaamAH . The effect of caffeine on diaphragmatic activity and tidal volume in preterm infants. Journal of Pediatrics2015;167(1):70-75. [DOI: 10.1016/j.jpeds.2015.04.040] [PMID: 25982138]">Kraaijenga 2015</a>). </p> </section> <section id="CD015462-sec-0016"> <h3 class="title" id="CD015462-sec-0016">Why it is important to do this review</h3> <p>This review compares caffeine to aminophylline and theophylline; it replaces and expands upon the aims of a previous Cochrane Review which examined only caffeine compared to theophylline (<a href="./references#CD015462-bbs2-0069" title="Henderson‐SmartDJ , SteerPA . Caffeine versus theophylline for apnea in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD000273. [DOI: 10.1002/14651858.CD000273.pub2] [PMID: 20091506]">Henderson‐Smart 2010</a>). We have expanded criteria for study inclusion and plan to perform subgroup analyses by treatment indication and type of methylxanthine used, when sufficient studies are included in meta‐analysis. A forthcoming Cochrane Review assesses the efficacy of methylxanthines compared with control (no intervention or placebo) (<a href="./references#CD015462-bbs2-0088" title="MarquesK , BruschettiniM , RoehrCC , DavisPG , FianderM , SollR . Methylxanthine for the prevention and treatment of apnea in preterm infants. Cochrane Database of Systematic Reviews2023, Issue [in press]. Art. No: CD013830. [DOI: 10.1002/14651858.CD013830.pub2]">Marques 2023</a>), preliminary results of which show that the use of methylxanthines in general might reduce respiratory morbidity and that caffeine might improve longer‐term development outcomes. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015462-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015462-sec-0017"></div> <p>To assess the effects of caffeine compared to aminophylline or theophylline in preterm infants at risk of apnea, with apnea, or in the peri‐extubation phase. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015462-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015462-sec-0018"></div> <section id="CD015462-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015462-sec-0020"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs) with parallel groups, quasi‐RCTs, and cluster‐randomized trials were eligible for inclusion in the review. We did not consider cross‐over RCTs as eligible for inclusion. We also deemed non‐randomized cohort studies ineligible for this review, because they are prone to bias due to confounding by indication or by residual confounding – both of which may influence results of the studies (<a href="./references#CD015462-bbs2-0065" title="FewellZ , Davey SmithG , SterneJA . The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. American Journal of Epidemiology2007;166(6):646-55. [DOI: 10.1093/aje/kwm165] [PMID: 17615092]">Fewell 2007</a>; <a href="./references#CD015462-bbs2-0084" title="KyriacouDN , LewisRJ . Confounding by indication in clinical research. JAMA2016;316(17):1818-9. [DOI: 10.1001/jama.2016.16435] [PMID: 27802529]">Kyriacou 2016</a>). </p> </section> <section id="CD015462-sec-0021"> <h4 class="title">Types of participants</h4> <p> <ul id="CD015462-list-0002"> <li> <p>For prevention trials: preterm infants born at less than 34 weeks' gestation, who are at risk of apnea. </p> </li> <li> <p>For treatment trials: preterm infants born at less than 37 weeks' gestation, with signs of apnea. </p> </li> <li> <p>For extubation trials: preterm infants born at less than 34 weeks' gestation, prior to planned extubation. </p> </li> </ul> </p> </section> <section id="CD015462-sec-0022"> <h4 class="title">Types of interventions</h4> <p>We included the following comparisons:</p> <p> <ul id="CD015462-list-0003"> <li> <p>caffeine versus aminophylline;</p> </li> <li> <p>caffeine versus theophylline.</p> </li> </ul> </p> <p>We included any duration and dose of treatment. We excluded studies on methylxanthines versus placebo (assessed in a separate Cochrane Review, <a href="./references#CD015462-bbs2-0088" title="MarquesK , BruschettiniM , RoehrCC , DavisPG , FianderM , SollR . Methylxanthine for the prevention and treatment of apnea in preterm infants. Cochrane Database of Systematic Reviews2023, Issue [in press]. Art. No: CD013830. [DOI: 10.1002/14651858.CD013830.pub2]">Marques 2023</a>), and studies on high‐dose versus low‐dose caffeine (assessed in a separate Cochrane Review, <a href="./references#CD015462-bbs2-0052" title="BruschettiniM , BrattströmP , RussoC , OnlandW , DavisPG , SollR . Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity. Cochrane Database of Systematic Reviews2023, Issue 4. Art. No: CD013873. [DOI: 10.1002/14651858.CD013873.pub2]">Bruschettini 2023</a>). </p> </section> <section id="CD015462-sec-0023"> <h4 class="title">Types of outcome measures</h4> <p>The following outcome measures did not form part of the eligibility criteria.</p> <section id="CD015462-sec-0024"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD015462-list-0004"> <li> <p>All‐cause mortality prior to hospital discharge (any setting)</p> </li> <li> <p>Composite outcome of moderate to severe neurodevelopmental disability at 18 to 26 months, as reported by study authors, using validated tools and including the following domains: cerebral palsy or gross motor disability; developmental delay more than two standard deviations (SDs) below population mean on a standardized test of development; visual impairment (visual acuity less than 6/60); hearing impairment (requiring amplification). If studies reported components of the composite outcome of neurodevelopmental disability (as detailed below), we presented them individually as primary outcomes: </p> <ol id="CD015462-list-0005"> <li> <p>cerebral palsy on clinical examination;</p> </li> <li> <p>gross motor disability (defined as ≥ level 2 according to the Gross Motor Function Classification System (GMFCS) (<a href="./references#CD015462-bbs2-0097" title="PalisanoR , RosenbaumP , WalterS , RussellD , WoodE , GaluppiB . Development and reliability of a system to classify gross motor function in children with cerebral palsy. Developmental Medicine and Child Neurology1997;39(4):214-23. [DOI: 10.1111/j.1469-8749.1997.tb07414.x] [PMID: 9183258]">Palisano 1997</a>); </p> </li> <li> <p>developmental delay more than two SDs below population mean on a standardized test of development (including assessment with Bayley or Griffith scales) (<a href="./references#CD015462-bbs2-0047" title="BayleyN . Bayley Scales of Infant Development–II. San Antonio (TX): Psychological Corporation, 1993.">Bayley 1993</a>; <a href="./references#CD015462-bbs2-0048" title="BayleyN . Bayley Scales of Infant and Toddler Development. San Antonio (TX): Harcourt Assessment, 2005.">Bayley 2005</a>; <a href="./references#CD015462-bbs2-0067" title="GriffithsR . The Abilities of Babies: A Study of Mental Measurement. London (UK): University of London Press, 1954.">Griffiths 1954</a>); </p> </li> <li> <p>mental development (intelligence quotient (IQ) &gt; 2 SD below the mean;</p> </li> <li> <p>visual impairment (vision &lt; 6/60 in both eyes);</p> </li> <li> <p>hearing impairment (requiring amplification).</p> </li> </ol> </li> </ol> </p> </section> <section id="CD015462-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD015462-list-0006"> <li> <p>Bronchopulmonary dysplasia (BPD)/chronic lung disease: defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age (<a href="./references#CD015462-bbs2-0078" title="JobeAH , BancalariE . Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine2001;163(7):1723-9. [DOI: 10.1164/ajrccm.163.7.2011060] [PMID: 11401896]">Jobe 2001</a>; <a href="./references#CD015462-bbs2-0094" title="National Institutes of Health. Report of workshop on bronchopulmonary dysplasia. In: NIH Publication No. 80-1660; 1978 December 4-6; Bethesda (MD). National Institutes of Health: Washington, DC, 1979.">NIH 1979</a>); and using the 'physiological definition' (<a href="./references#CD015462-bbs2-0109" title="WalshMC , YaoQ , GettnerP , HaleE , CollinsM , HensmanA , et al, National Institute of Child Health and Human Development Neonatal Research Network. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics2004;114(5):1305-11. [DOI: 10.1542/peds.2004-0204] [PMID: 15520112]">Walsh 2004</a>) </p> </li> <li> <p>Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines </p> </li> <li> <p>Duration of hospital stay</p> </li> <li> <p>Seizures (clinically diagnosed)</p> </li> <li> <p>Failure to extubate within one week of commencing treatment</p> </li> <li> <p>Reintubation within one week of commencing treatment</p> </li> <li> <p>Failed apnea reduction after two to seven days (less than 50% reduction in apnea), for infants treated for apnea </p> </li> <li> <p>Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after 24 hours from commencing treatment, in a 24‐hour period, and over one week </p> </li> <li> <p>Apnea: number of infants with at least one episode (defined as interruption of breathing for more than 20 seconds) after 24 hours of commencing treatment, in a 24‐hour period, and over one week </p> </li> <li> <p>Number of days of respiratory support (mechanical ventilation; continuous positive airway pressure [CPAP]; high‐flow nasal cannula; non‐invasive positive‐pressure ventilation [NIPPV]) </p> </li> <li> <p>Number of days of mechanical ventilation</p> </li> <li> <p>Number of days of supplemental oxygen</p> </li> <li> <p>Need for mechanical ventilation (yes/no)</p> </li> <li> <p>Need for non‐invasive respiratory support (CPAP, NIPPV, high‐flow nasal cannulae)</p> </li> <li> <p>Neonatal mortality (up to 28 days)</p> </li> <li> <p>Intraventricular hemorrhage on brain ultrasound (any; and severe [Papile grade 3 to 4]) (<a href="./references#CD015462-bbs2-0098" title="PapileLA , BursteinJ , BursteinR , KofflerH . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics1978;92(4):529-534. [DOI: 10.1016/s0022-3476(78)80282-0] [PMID: 305471]">Papile 1978</a>) </p> </li> <li> <p>Cerebellar hemorrhage on brain ultrasound (yes/no)</p> </li> <li> <p>Periventricular leukomalacia (<a href="./references#CD015462-bbs2-0057" title="De VriesLS , EkenP , DubowitzLM . The spectrum of leukomalacia using cranial ultrasound. Behavioural Brain Research1992;49(1):1-6. [CENTRAL: 10.1016/s0166-4328(05)80189-5] [PMID: 1388792]">De Vries 1992</a>) </p> </li> <li> <p>Necrotizing enterocolitis (NEC) (defined as Bell stage 2 or greater) (<a href="./references#CD015462-bbs2-0049" title="BellMJ , TernbergJL , FeiginRD , KeatingJP , MarshallR , BartonL , et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery1978;187(1):1-7. [DOI: 10.1097/00000658-197801000-00001] [PMID: 413500]">Bell 1978</a>) </p> </li> <li> <p>Patent ductus arteriosus (PDA) requiring treatment (cyclo‐oxygenase inhibitors or surgical ligation) </p> </li> <li> <p>Retinopathy of prematurity (ROP) (any ROP; and severe ROP [stage 3 or greater]) (<a href="./references#CD015462-bbs2-0076" title="International Committee for the Classification of Retinopathy of Prematurity (ICCROP). The international classification of retinopathy of prematurity revisited. Archives of Ophthalmology2005;123(7):991-9. [DOI: 10.1001/archopht.123.7.991] [PMID: 16009843]">ICCROP 2005</a>) </p> </li> <li> <p>Cost of neonatal care</p> </li> <li> <p>Each component of the composite outcome 'major neurodevelopmental disability' (described in <a href="#CD015462-sec-0024">Primary outcomes</a>) </p> </li> </ol> </p> </section> </section> </section> <section id="CD015462-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD015462-sec-0027"> <h4 class="title">Electronic searches</h4> <p>Cochrane Sweden's Information Specialist developed the search strategies (<a href="./appendices#CD015462-sec-0097">Appendix 1</a>). We conducted searches in the following databases, without date, language, or publication‐type restrictions: </p> <p> <ul id="CD015462-list-0007"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), via Wiley (CENTRAL 2023, Issue 2, 15 February 2023) </p> </li> <li> <p>MEDLINE via PubMed (1966 to 14 February 2023)</p> </li> <li> <p>Embase, via Elsevier (1974 to 15 February 2023)</p> </li> <li> <p>Epistemonikos (<a href="https://www.epistemonikos.org/" target="_blank">https://www.epistemonikos.org</a>) (15 February 2023) </p> </li> </ul> </p> <p>We used methodological filters to restrict retrieval to RCTs or quasi‐RCTs. We used a systematic review filter to identify systematic reviews related to the topic of this review; we limited this search to reviews published from 2021 to 15 February 2023. </p> </section> <section id="CD015462-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We identified trial registration records by independent searches (run on 15 February 2023) of the US National Library of Medicine (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov),</a> and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; <a href="https://www.who.int/clinical-trials-registry-platform/the-ictrp-search-portal" target="_blank">www.who.int/clinical-trials-registry-platform/the-ictrp-search-portal</a>). </p> <p>We screened the reference lists of included studies for studies not identified by the database searches. </p> <p>We searched for errata or retractions for included studies published on PubMed (<a href="https://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>). </p> <p>We conducted a gray literature search to identify reports of trials conducted by or referenced in research by: the Community Research and Development Information Service of the European Commission (CORDIS EU, <a href="https://cordis.europa.eu/" target="_blank">cordis.europa.eu/</a>); the National Institute for Health and Care Excellence (NICE); and the National Health Service Greater Glasgow and Clyde (NHSGGC) Paediatrics for Health Professionals (<a href="https://www.clinicalguidelines.scot.nhs.uk/nhsggc-guidelines/" target="_blank">www.clinicalguidelines.scot.nhs.uk/nhsggc-guidelines/</a>). We identified sources by consulting the Technical Supplement of the searching chapter in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015462-bbs2-0085" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane 2021. Available from www.training.cochrane.org/handbook.">Lefebvre 2021</a>): <a href="https://training.cochrane.org/handbook/current/chapter-04-appendix-resources" target="_blank">training.cochrane.org/handbook/current/chapter-04-appendix-resources</a>. </p> </section> </section> <section id="CD015462-sec-0029"> <h3 class="title" id="CD015462-sec-0029">Data collection and analysis</h3> <section id="CD015462-sec-0030"> <h4 class="title">Selection of studies</h4> <p>We planned to use <a href="https://community.cochrane.org/sites/default/files/uploads/S4M_Users_FAQs.pdf" target="_blank">Cochrane’s Screen4Me</a> workflow to help assess the search results. However, this was unnecessary as we identified fewer than 1000 records, following de‐duplication. </p> <p>We downloaded all titles and abstracts retrieved by electronic searching to a reference management database and removed duplicates. Two review authors (LM, AS) independently screened titles and abstracts for inclusion. We retrieved potentially eligible full‐text study reports/publications. Two review authors (LM, AS) independently screened the full texts, identified studies for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreement through discussion or, if required, we consulted a third review author (MB). We listed studies that initially appeared to meet the inclusion criteria but that we later excluded in <a href="./references#CD015462-sec-0124" title="">Characteristics of excluded studies</a>. We collated multiple reports of the same study so that each study, rather than each report, is the unit of interest in the review. We also provided any information we could obtain about ongoing studies. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD015462-bbs2-0086" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100] [PMID: 19621070]">Liberati 2009</a>) and <a href="./references#CD015462-sec-0123" title="">Characteristics of included studies</a>. </p> </section> <section id="CD015462-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (LM, AS) independently extracted data using a data extraction form integrated with a modified version of the Cochrane Effective Practice and Organisation of Care Group data collection checklist (<a href="./references#CD015462-bbs2-0063" title="Cochrane Effective Practice and Organisation of Care (EPOC). Data extraction and management. EPOC resources for review authors, 2017. epoc.cochrane.org/resources/epoc-resources-review-authors (accessed prior to 13 February 2023).">EPOC 2017</a>). We piloted the form within the review team using a sample of included studies. </p> <p>We extracted the following characteristics from each included study.</p> <p> <ul id="CD015462-list-0008"> <li> <p>Administrative details: study author(s); published or unpublished; year of publication; year in which study was conducted; presence of vested interest; details of other relevant papers cited. </p> </li> <li> <p>Methods: study design; type, duration, and completeness of follow‐up (e.g. greater than 80%); country and location of study; informed consent; ethics approval. </p> </li> <li> <p>Participants: sex, birth weight, gestational age, number of participants.</p> </li> <li> <p>Interventions: initiation, dose, and duration of administration.</p> </li> <li> <p>Outcomes as described above in <a href="#CD015462-sec-0023">Types of outcome measures</a>. </p> </li> </ul> </p> <p>We resolved any disagreements through discussion. We have described ongoing studies identified by our search in <a href="./references#CD015462-sec-0126" title="">Characteristics of ongoing studies</a>, detailing the primary author, research question(s), methods, outcome measures, and an estimate of the reporting date. </p> <p>If any queries arose, or in cases for which additional data were required, we contacted study investigators/authors for clarification. Two review authors (LM, AS) used Cochrane statistical software for data entry (<a href="./references#CD015462-bbs2-0101" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). We planned to replace any standard error of the mean (SEM) by the corresponding SD. </p> </section> <section id="CD015462-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (LM, AS) independently assessed the risk of bias (assigning ratings of low, high, or unclear risk) of all included trials using the Cochrane risk of bias tool for the following domains (<a href="./references#CD015462-bbs2-0071" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>): </p> <p> <ul id="CD015462-list-0009"> <li> <p>random sequence generation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>blinding of participants and personnel (performance bias);</p> </li> <li> <p>blinding of outcome assessment (detection bias);</p> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective reporting (reporting bias);</p> </li> <li> <p>any other bias.</p> </li> </ul> </p> <p>We resolved any disagreements through discussion or by consulting a third review author (MB). See <a href="./appendices#CD015462-sec-0107">Appendix 2</a> for a more detailed description of risk of bias for each domain. We assessed overall risk of bias according to three categories, as follows. </p> <p> <ul id="CD015462-list-0010"> <li> <p>Low risk of bias: we classified the outcome of a trial as being at low risk of bias overall only if we classified all domains as being at low risk of bias. </p> </li> <li> <p>Unclear risk of bias: we classified the outcome of a trial as being at unclear risk of bias overall if we classified one or more domains as unclear risk and no domain as high risk of bias. </p> </li> <li> <p>High risk of bias: we classified the outcome of a trial as being at high risk of bias overall if we classified at least one domain as being at high risk of bias. </p> </li> </ul> </p> </section> <section id="CD015462-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we have presented results using risk ratios (RR) and risk differences (RD) with 95% confidence intervals (CIs). We calculated the number needed to treat for an additional beneficial outcome (NNTB), or number needed to treat for an additional harmful outcome (NNTH) with 95% CIs if there was a statistically significant reduction (or increase) in RD. </p> <p>For continuous data, we used the mean difference (MD) when outcomes were measured in the same way between trials. We used the standardized mean difference (SMD) to combine trials that measured the same outcome but used different methods. We planned to convert mean to median and estimate the standard deviation as the interquartile range (IQR)/1.35, where trials reported continuous data as median and IQR and data passed the test of skewness. However, this step was not necessary for this version of the review. </p> </section> <section id="CD015462-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>We performed the primary analysis per individual randomized. For cluster‐randomized trials, we had planned to extract information on the study design and unit of analysis for each study, indicating whether clustering of observations was present due to allocation to the intervention at the group level or clustering of individually‐randomized observations (e.g. patients within clinics). However, we did not include any cluster‐randomized trials. </p> <p>If any trials had multiple arms that were compared against the same control condition that would be included in the same meta‐analysis, we planned to either combine groups to create a single pair‐wise comparison, or select one pair of interventions and exclude the others. This step was unnecessary in this version of the review. </p> </section> <section id="CD015462-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We planned to carry out analysis on an intention‐to‐treat (ITT) basis for all included outcomes. Whenever possible, we analyzed all participants in the treatment group to which they were randomized, regardless of the actual treatment received. Where we identified important missing data (in the outcomes) or unclear data, we requested the missing data by contacting the original investigators. We made explicit the assumptions of any methods used to deal with missing data. We planned to perform sensitivity analyses to assess how robust the results were to decisions we made about how to deal with missing data. We discuss the potential impact of missing data on the findings of the review in the <a href="#CD015462-sec-0085">Discussion</a> section. </p> </section> <section id="CD015462-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We have described the clinical diversity and methodological variability of the evidence in the review text and in <a href="./references#CD015462-sec-0123" title="">Characteristics of included studies</a>, including design features, population characteristics, and intervention details. </p> <p>To assess statistical heterogeneity, we visually inspected forest plots and described the direction and magnitude of effects and the degree of overlap between confidence intervals. We also considered the statistics generated in forest plots that measure statistical heterogeneity. We used the I² statistic to quantify inconsistency among the trials in each analysis. We also considered the P value from the Chi² test to assess if this heterogeneity was significant (P &lt; 0.1). When we identified substantial heterogeneity, we had planned to report the finding and explore possible explanatory factors using prespecified subgroup analysis. However, we could not perform subgroup analysis due to the paucity of studies in each analysis. </p> <p>We graded the degree of heterogeneity as:</p> <p> <ul id="CD015462-list-0011"> <li> <p>0% to 40% might not represent important heterogeneity;</p> </li> <li> <p>30% to 60% may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90% may represent substantial heterogeneity;</p> </li> <li> <p>more than 75% may represent considerable heterogeneity.</p> </li> </ul> </p> <p>A rough guideline was used to interpret the I<sup>2</sup> value rather than a simple threshold, and our interpretation took into account an understanding that measures of heterogeneity (I<sup>2</sup> and Tau) are estimated with high uncertainty when the number of studies is small (<a href="./references#CD015462-bbs2-0058" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). </p> </section> <section id="CD015462-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias by comparing studies' stated primary and secondary outcomes with the reported outcomes. Where study protocols were available, we compared these to the full publications to determine the likelihood of reporting bias. Studies using the interventions in a potentially eligible infant population but not reporting on any of the primary and secondary outcomes are documented in the <a href="./references#CD015462-sec-0123" title="">Characteristics of included studies</a> tables. </p> <p>We planned to use the funnel plots to screen for publication bias where there was a sufficient number of studies (&gt; 10) reporting the same outcome. If publication bias was suggested by a significant asymmetry of the funnel plot on visual assessment, we planned to incorporate this in our assessment of the certainty of the evidence (<a href="./references#CD015462-bbs2-0061" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34. [PMID: 9492687]">Egger 1997</a>). As our review included few studies eligible for meta‐analysis, our ability to detect publication bias was limited, and we simply noted our inability to rule out possible publication bias or small study effects. </p> </section> <section id="CD015462-sec-0038"> <h4 class="title">Data synthesis</h4> <p>When we identified multiple studies that we considered to be sufficiently similar, we performed meta‐analysis using Review Manager Web (<a href="./references#CD015462-bbs2-0101" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). For categorical outcomes, we calculated the typical estimates of RR and RD, each with its 95% CI; for continuous outcomes, we calculated the MD or the SMD, each with its 95% CI. We used a fixed‐effect model to combine data where it was reasonable to assume that studies were estimating the same underlying treatment effect. When we judged meta‐analysis to be inappropriate, we analyzed and interpreted individual trials separately. When there was evidence of clinical heterogeneity, we tried to explain the heterogeneity based on the different study characteristics and subgroup analyses. </p> </section> <section id="CD015462-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Tests for subgroup differences in effects are to be interpreted with caution, given the potential for confounding with other study characteristics and the observational nature of the comparisons (<a href="./references#CD015462-bbs2-0072" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020a</a>). In particular, subgroup analyses with fewer than five studies per category are likely to be inadequate to ascertain valid difference in effects; we did not plan to present these in our results. If subgroup comparisons were possible, we planned stratified meta‐analysis and a formal statistical test for interaction to examine subgroup differences that could account for effect heterogeneity (e.g. Cochran’s Q test, meta‐regression) (<a href="./references#CD015462-bbs2-0072" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020a</a>). </p> <p>We planned to carry out the following subgroup analyses of factors that may contribute to heterogeneity in the effects of the intervention. </p> <p> <ul id="CD015462-list-0012"> <li> <p>Gestational age: less than 28 weeks; 28 to 32 weeks; 32 weeks or greater.</p> </li> <li> <p>Birth weight: less than 1000 g; 1000 g to 1500 g; more than 1500 g.</p> </li> <li> <p>For prevention studies only: intubation (intubated newborns; non‐intubated newborns).</p> </li> </ul> </p> <p>We did not perform any subgroup analyses in this version of the review due to the paucity of studies in each meta‐analysis. </p> </section> <section id="CD015462-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>Given that there is no formal statistical test that can be used for sensitivity analysis, we planned to provide informal comparisons between the different ways of estimating the effect under different assumptions. Changes in the P values should not be used to judge whether there is a difference between the main analysis and sensitivity analysis, since statistical significance may be lost with fewer studies included. </p> <p>We planned to report sensitivity analysis results in tables rather than forest plots.</p> </section> <section id="CD015462-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD015462-bbs2-0106" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020</a>), to assess the certainty of evidence for the following (clinically relevant) outcomes. </p> <p> <ul id="CD015462-list-0013"> <li> <p>All‐cause mortality prior to hospital discharge.</p> </li> <li> <p>Moderate to severe neurodevelopmental disability at 18 to 26 months, as reported by study authors, using validated tools and including the following domains: cerebral palsy or gross motor disability; developmental delay more than two SDs below population mean on a standardized test of development; visual impairment (visual acuity less than 6/60); hearing impairment (requiring amplification). Components of neurodevelopmental disability are detailed below: </p> <ul id="CD015462-list-0014"> <li> <p>cerebral palsy on clinical examination;</p> </li> <li> <p>gross motor disability (defined as ≥ level 2 according to the GMFCS (<a href="./references#CD015462-bbs2-0097" title="PalisanoR , RosenbaumP , WalterS , RussellD , WoodE , GaluppiB . Development and reliability of a system to classify gross motor function in children with cerebral palsy. Developmental Medicine and Child Neurology1997;39(4):214-23. [DOI: 10.1111/j.1469-8749.1997.tb07414.x] [PMID: 9183258]">Palisano 1997</a>); </p> </li> <li> <p>developmental delay more than two SDs below population mean on a standardized test of development (including assessment with Bayley or Griffith scales) (<a href="./references#CD015462-bbs2-0047" title="BayleyN . Bayley Scales of Infant Development–II. San Antonio (TX): Psychological Corporation, 1993.">Bayley 1993</a>; <a href="./references#CD015462-bbs2-0048" title="BayleyN . Bayley Scales of Infant and Toddler Development. San Antonio (TX): Harcourt Assessment, 2005.">Bayley 2005</a>; <a href="./references#CD015462-bbs2-0067" title="GriffithsR . The Abilities of Babies: A Study of Mental Measurement. London (UK): University of London Press, 1954.">Griffiths 1954</a>); </p> </li> <li> <p>mental development (IQ &gt; 2 SD below the mean);</p> </li> <li> <p>visual impairment (vision &lt; 6/60 in both eyes);</p> </li> <li> <p>hearing impairment (requiring amplification).</p> </li> </ul> </li> <li> <p>BPD/chronic lung disease at 36 weeks' postmenstrual age.</p> </li> <li> <p>Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine. </p> </li> <li> <p>Duration of hospital stay.</p> </li> <li> <p>Seizures (clinically diagnosed).</p> </li> </ul> </p> <p>Two review authors (AS, MB) independently assessed the certainty of the evidence for each of the outcomes above. We considered evidence from RCTs as high certainty, downgrading the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates, and presence of publication bias. We used <a href="./references#CD015462-bbs2-0066" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 5 March 2023. Available at gradepro.org.">GRADEpro GDT</a> Guideline Development Tool to create <a href="./full#CD015462-tbl-0001">summary of findings Table 1</a> to report the certainty of the evidence. </p> <p>The GRADE approach results in an assessment of the certainty of a body of evidence in one of the following four grades. </p> <p> <ul id="CD015462-list-0015"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015462-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015462-sec-0042"></div> <section id="CD015462-sec-0043"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD015462-sec-0123" title="">Characteristics of included studies</a>; <a href="./references#CD015462-sec-0124" title="">Characteristics of excluded studies</a>; <a href="./references#CD015462-sec-0125" title="">Characteristics of studies awaiting classification</a>; <a href="./references#CD015462-sec-0126" title="">Characteristics of ongoing studies</a>. </p> <section id="CD015462-sec-0044"> <h4 class="title">Results of the search</h4> <p>The search identified a total of 1331 references (1296 via databases; 35 via other methods). After removal of 447 duplicates, 884 records remained. We excluded 840 records based on title/abstract and reviewed 44 full texts. We included 22 studies (27 reports); excluded 12 studies (12 reports); classified 1 study (1 report) as awaiting classification; and identified 4 ongoing studies (4 reports). Details of study selection are presented in <a href="#CD015462-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD015462-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD015462-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD015462-sec-0045"> <h4 class="title">Included studies</h4> <p>We included 22 trials recruiting 1776 infants. Details of the trials are described in the <a href="./references#CD015462-sec-0123" title="">Characteristics of included studies</a>. </p> <p>Three trials were conducted for prevention of apnea (<a href="./references#CD015462-bbs2-0009" title="LarsenPB , BrendstrupL , SkovL , FlachsH . Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. Acta Paediatrica1995;84(4):360-4. [DOI: 10.1111/j.1651-2227.1995.tb13649.x] [PMID: 7795341]">Larsen 1995</a>; <a href="./references#CD015462-bbs2-0011" title="LundstrømKE , LarsenPB , BrendstrupL , SkovL , GreisenG . Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or aminophylline. Acta Paediatrica, International Journal of Paediatrics1995;84(1):6-9. [DOI: 10.1111/j.1651-2227.1995.tb13474.x] [PMID: 7734901]">Lundstrøm 1995</a>; <a href="./references#CD015462-bbs2-0013" title="SchellackN , GousAGS , MawelaPB . Caffeine versus aminophylline for the prevention of apnoea of prematurity in a teaching hospital in South Africa. South African Family Practice2015;57(3):140-5. [DOI: 10.1080/20786190.2014.983310] [EMBASE: L605278311]">Schellack 2015</a>). Thirteen trials were conducted for treatment of apnea (<a href="./references#CD015462-bbs2-0001" title="BairamA , BoutroyMJ , BadonnelY , VertP . The choice between theophylline and caffeine in the treatment of apneas of prematurity. Archives Francaises de Pediatrie1990;47(6):461-5. [PMID: 2206108]BairamA , BoutroyMJ , BadonnelY , VertP . Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. Journal of Pediatrics1987;110(4):636-9. [DOI: 10.1016/s0022-3476(87)80569-3] [PMID: 3559816]">Bairam 1987</a>; <a href="./references#CD015462-bbs2-0002" title="BrouardC , MorietteG , MuratI , FlouvatB , PajotN , WaltiH , et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. American Journal of Diseases of Children1985;139(7):698-700. [DOI: 10.1001/archpedi.1985.02140090060028] [PMID: 4014092]">Brouard 1985</a>; <a href="./references#CD015462-bbs2-0003" title="DaniC , BertiniG , RealiMF , TronchinM , WiechmannL , MartelliE , et al. Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment. Biology of the Neonate2000;78(1):27-32. [DOI: 10.1159/000014243] [PMID: 10878419]">Dani 2000</a>; <a href="./references#CD015462-bbs2-0004" title="FangS , SherwoodRA , GamsuHR , MarsdenJT , PetersTJ , GreenoughA . Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. European Journal of Pediatrics1998;157(5):406-9. [DOI: 10.1007/s004310050840] [PMID: 9625339]">Fang 1998</a>; <a href="./references#CD015462-bbs2-0005" title="FuglsangG , NielsenK , Kjaer NielsenL , SennelsF , JakobsenP , ThelleT . The effect of caffeine compared with theophylline in the treatment of idiopathic apnea in premature infants. Acta Paediatrica1989;78(5):786-8. [DOI: 10.1111/j.1651-2227.1989.tb11147.x] [PMID: 2688355]">Fuglsang 1989</a>; <a href="./references#CD015462-bbs2-0006" title="GharehbaghiMM , TaheriM , GharabaghiF . Comparing the effect of caffeine and aminophylline on the osteopenia of prematurity in neonates. Journal of Pioneering Medical Sciences2016;6(3):84-88. [LINK: www.jpmsonline.com/jpms-vol6-issue3-pages84-88-oa-text-only-file-2/]">Gharehbaghi 2016</a>; <a href="./references#CD015462-bbs2-0007" title="HabibiM , MahyarA , NikdehghanS . Effect of caffeine and aminophylline on apnea of prematurity. Iranian Journal of Neonatology2019;10(2):37-41. [DOI: 10.22038/ijn.2019.33041.1468] [EMBASE: L2002904738]">Habibi 2019</a>; <a href="./references#CD015462-bbs2-0012" title="ScanlonJE , ChinKC , MorganME , DurbinGM , HaleKA , BrownSS . Caffeine or theophylline for neonatal apnoea?Archives of Disease in Childhood1992;67(4 Spec No):425-8. [DOI: 10.1136/adc.67.4_spec_no.425] [PMID: 1586184]">Scanlon 1992</a>; <a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>; <a href="./references#CD015462-bbs2-0018" title="XiangS , LiuD , MaY , ZhangN , LiH , DuX , et al. The effect of cpap combined with caffeine citrate on apnea of prematurity. International Journal of Clinical and Experimental Medicine2021;14(1):639-45. [EMBASE: L2005953778]">Xiang 2021</a>; <a href="./references#CD015462-bbs2-0019" title="YangD , ZhouB , JinB , LiuX , WangY . Amplitude integrated electroencephalogram study of the effect of caffeine citrate on brain development in low weight infants with apnea. Iranian Journal of Public Health2019;48(7):1278-83. [PMID: 31497549]">Yang 2019</a>; <a href="./references#CD015462-bbs2-0020" title="YuM , HuangJH , ZhuR , ZhangXZ , WuWY , WenXH . Effect of caffeine citrate on early pulmonary function in preterm infants with apnea. Zhongguo Dang Dai Er Ke Za Zhi2016;18(3):206-10. [DOI: 10.7499/j.issn.1008-8830.2016.03.003] [PMID: 26975815]">Yu 2016</a>; <a href="./references#CD015462-bbs2-0022" title="ZulqarnainA , HussainM , SuleriKM , Ali ChZ . Comparison of caffeine versus theophylline for apnea of prematurity. Pakistan Journal of Medical Sciences2019;35(1):113-6. [DOI: 10.12669/pjms.35.1.94] [PMID: 30881407]">Zulqarnain 2019</a>). Two trials were conducted for extubation (<a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>; <a href="./references#CD015462-bbs2-0016" title="SimsME , RangasamyR , LeeS , ChungH , CohenJ , WaltherFJ . Comparative evaluation of caffeine and theophylline for weaning premature infants from the ventilator. American Journal of Perinatology Reports1989;6(1):72-5. [DOI: 10.1055/s-2007-999549] [PMID: 2642707]">Sims 1989</a>). Three trials had a mixed population: infants enrolled for different indications were included (<a href="./references#CD015462-bbs2-0010" title="LaubscherB , GreenoughA , DimitriouG . Comparative effects of theophylline and caffeine on respiratory function of prematurely born infants. Early Human Development1998;50(2):185-92. [DOI: 10.1016/s0378-3732(97)00038-6] [PMID: 9483391]">Laubscher 1998</a>; <a href="./references#CD015462-bbs2-0017" title="SkouroliakouM , BacopoulouF , MarkantonisSL . Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. Journal of Paediatrics and Child Health2009;45(10):587-92. [DOI: 10.1111/j.1440-1754.2009.01570.x] [PMID: 19751376]">Skouroliakou 2009</a>; <a href="./references#CD015462-bbs2-0021" title="ZanardoV , DaniC , TrevisanutoD , MeneghettiS , GuglielmiA , ZacchelloG , et al. Methylxanthines increase renal calcium excretion in preterm infants. Biology of the Neonate1995;68(3):169-74. [DOI: 10.1159/000244234] [PMID: 8534781]">Zanardo 1995</a>). In one trial, indication for caffeine administration was not reported (<a href="./references#CD015462-bbs2-0008" title="KumarSP , MehtaPN , BradleyBS , EzhuthachanSG . Documented monitoring (DM) shows theophylline (T) to be more effective than caffeine (C) in prematurity apnea (PA). Pediatric Research1992;31:208A. ">Kumar 1992</a>). </p> <p>Three studies were conducted in Denmark (<a href="./references#CD015462-bbs2-0005" title="FuglsangG , NielsenK , Kjaer NielsenL , SennelsF , JakobsenP , ThelleT . The effect of caffeine compared with theophylline in the treatment of idiopathic apnea in premature infants. Acta Paediatrica1989;78(5):786-8. [DOI: 10.1111/j.1651-2227.1989.tb11147.x] [PMID: 2688355]">Fuglsang 1989</a>; <a href="./references#CD015462-bbs2-0009" title="LarsenPB , BrendstrupL , SkovL , FlachsH . Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. Acta Paediatrica1995;84(4):360-4. [DOI: 10.1111/j.1651-2227.1995.tb13649.x] [PMID: 7795341]">Larsen 1995</a>; <a href="./references#CD015462-bbs2-0011" title="LundstrømKE , LarsenPB , BrendstrupL , SkovL , GreisenG . Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or aminophylline. Acta Paediatrica, International Journal of Paediatrics1995;84(1):6-9. [DOI: 10.1111/j.1651-2227.1995.tb13474.x] [PMID: 7734901]">Lundstrøm 1995</a>), three in China (<a href="./references#CD015462-bbs2-0018" title="XiangS , LiuD , MaY , ZhangN , LiH , DuX , et al. The effect of cpap combined with caffeine citrate on apnea of prematurity. International Journal of Clinical and Experimental Medicine2021;14(1):639-45. [EMBASE: L2005953778]">Xiang 2021</a>; <a href="./references#CD015462-bbs2-0019" title="YangD , ZhouB , JinB , LiuX , WangY . Amplitude integrated electroencephalogram study of the effect of caffeine citrate on brain development in low weight infants with apnea. Iranian Journal of Public Health2019;48(7):1278-83. [PMID: 31497549]">Yang 2019</a>; <a href="./references#CD015462-bbs2-0020" title="YuM , HuangJH , ZhuR , ZhangXZ , WuWY , WenXH . Effect of caffeine citrate on early pulmonary function in preterm infants with apnea. Zhongguo Dang Dai Er Ke Za Zhi2016;18(3):206-10. [DOI: 10.7499/j.issn.1008-8830.2016.03.003] [PMID: 26975815]">Yu 2016</a>), three in the UK (<a href="./references#CD015462-bbs2-0004" title="FangS , SherwoodRA , GamsuHR , MarsdenJT , PetersTJ , GreenoughA . Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. European Journal of Pediatrics1998;157(5):406-9. [DOI: 10.1007/s004310050840] [PMID: 9625339]">Fang 1998</a>; <a href="./references#CD015462-bbs2-0010" title="LaubscherB , GreenoughA , DimitriouG . Comparative effects of theophylline and caffeine on respiratory function of prematurely born infants. Early Human Development1998;50(2):185-92. [DOI: 10.1016/s0378-3732(97)00038-6] [PMID: 9483391]">Laubscher 1998</a>; <a href="./references#CD015462-bbs2-0012" title="ScanlonJE , ChinKC , MorganME , DurbinGM , HaleKA , BrownSS . Caffeine or theophylline for neonatal apnoea?Archives of Disease in Childhood1992;67(4 Spec No):425-8. [DOI: 10.1136/adc.67.4_spec_no.425] [PMID: 1586184]">Scanlon 1992</a>), two in France (<a href="./references#CD015462-bbs2-0001" title="BairamA , BoutroyMJ , BadonnelY , VertP . The choice between theophylline and caffeine in the treatment of apneas of prematurity. Archives Francaises de Pediatrie1990;47(6):461-5. [PMID: 2206108]BairamA , BoutroyMJ , BadonnelY , VertP . Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. Journal of Pediatrics1987;110(4):636-9. [DOI: 10.1016/s0022-3476(87)80569-3] [PMID: 3559816]">Bairam 1987</a>; <a href="./references#CD015462-bbs2-0002" title="BrouardC , MorietteG , MuratI , FlouvatB , PajotN , WaltiH , et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. American Journal of Diseases of Children1985;139(7):698-700. [DOI: 10.1001/archpedi.1985.02140090060028] [PMID: 4014092]">Brouard 1985</a>), two in Iran (<a href="./references#CD015462-bbs2-0006" title="GharehbaghiMM , TaheriM , GharabaghiF . Comparing the effect of caffeine and aminophylline on the osteopenia of prematurity in neonates. Journal of Pioneering Medical Sciences2016;6(3):84-88. [LINK: www.jpmsonline.com/jpms-vol6-issue3-pages84-88-oa-text-only-file-2/]">Gharehbaghi 2016</a>; <a href="./references#CD015462-bbs2-0007" title="HabibiM , MahyarA , NikdehghanS . Effect of caffeine and aminophylline on apnea of prematurity. Iranian Journal of Neonatology2019;10(2):37-41. [DOI: 10.22038/ijn.2019.33041.1468] [EMBASE: L2002904738]">Habibi 2019</a>), two in India (<a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>; <a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>), two in Italy (<a href="./references#CD015462-bbs2-0003" title="DaniC , BertiniG , RealiMF , TronchinM , WiechmannL , MartelliE , et al. Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment. Biology of the Neonate2000;78(1):27-32. [DOI: 10.1159/000014243] [PMID: 10878419]">Dani 2000</a>; <a href="./references#CD015462-bbs2-0021" title="ZanardoV , DaniC , TrevisanutoD , MeneghettiS , GuglielmiA , ZacchelloG , et al. Methylxanthines increase renal calcium excretion in preterm infants. Biology of the Neonate1995;68(3):169-74. [DOI: 10.1159/000244234] [PMID: 8534781]">Zanardo 1995</a>), and one each in Greece (<a href="./references#CD015462-bbs2-0017" title="SkouroliakouM , BacopoulouF , MarkantonisSL . Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. Journal of Paediatrics and Child Health2009;45(10):587-92. [DOI: 10.1111/j.1440-1754.2009.01570.x] [PMID: 19751376]">Skouroliakou 2009</a>), Pakistan (<a href="./references#CD015462-bbs2-0022" title="ZulqarnainA , HussainM , SuleriKM , Ali ChZ . Comparison of caffeine versus theophylline for apnea of prematurity. Pakistan Journal of Medical Sciences2019;35(1):113-6. [DOI: 10.12669/pjms.35.1.94] [PMID: 30881407]">Zulqarnain 2019</a>), South Africa (<a href="./references#CD015462-bbs2-0013" title="SchellackN , GousAGS , MawelaPB . Caffeine versus aminophylline for the prevention of apnoea of prematurity in a teaching hospital in South Africa. South African Family Practice2015;57(3):140-5. [DOI: 10.1080/20786190.2014.983310] [EMBASE: L605278311]">Schellack 2015</a>), and the USA (<a href="./references#CD015462-bbs2-0016" title="SimsME , RangasamyR , LeeS , ChungH , CohenJ , WaltherFJ . Comparative evaluation of caffeine and theophylline for weaning premature infants from the ventilator. American Journal of Perinatology Reports1989;6(1):72-5. [DOI: 10.1055/s-2007-999549] [PMID: 2642707]">Sims 1989</a>). One study was published in Mandarin and translated to English (<a href="./references#CD015462-bbs2-0020" title="YuM , HuangJH , ZhuR , ZhangXZ , WuWY , WenXH . Effect of caffeine citrate on early pulmonary function in preterm infants with apnea. Zhongguo Dang Dai Er Ke Za Zhi2016;18(3):206-10. [DOI: 10.7499/j.issn.1008-8830.2016.03.003] [PMID: 26975815]">Yu 2016</a>). </p> <p>All participants were preterm infants with a gestational age between 24 and 34 weeks. Sample sizes varied widely, from 16 (<a href="./references#CD015462-bbs2-0002" title="BrouardC , MorietteG , MuratI , FlouvatB , PajotN , WaltiH , et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. American Journal of Diseases of Children1985;139(7):698-700. [DOI: 10.1001/archpedi.1985.02140090060028] [PMID: 4014092]">Brouard 1985</a>) to 240 (<a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>). In all but one study, participants were divided into two groups and randomized to receive caffeine or other methylxanthines. Caffeine was administered orally, intramuscularly, or intravenously. The loading dose of caffeine citrate ranged from 20 to 25 mg/kg, except for two studies that used 10 mg/kg (<a href="./references#CD015462-bbs2-0004" title="FangS , SherwoodRA , GamsuHR , MarsdenJT , PetersTJ , GreenoughA . Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. European Journal of Pediatrics1998;157(5):406-9. [DOI: 10.1007/s004310050840] [PMID: 9625339]">Fang 1998</a>; <a href="./references#CD015462-bbs2-0010" title="LaubscherB , GreenoughA , DimitriouG . Comparative effects of theophylline and caffeine on respiratory function of prematurely born infants. Early Human Development1998;50(2):185-92. [DOI: 10.1016/s0378-3732(97)00038-6] [PMID: 9483391]">Laubscher 1998</a>). The maintenance dose ranged from 2.5 to 10 mg/kg. Doses of theophylline and aminophylline ranged from 4.8 to 7.5 mg/kg (loading dose), and from 1 to 3.75 mg/kg (maintenance dose) every 12 hours. In six studies, theophylline was given every eight hours (<a href="./references#CD015462-bbs2-0006" title="GharehbaghiMM , TaheriM , GharabaghiF . Comparing the effect of caffeine and aminophylline on the osteopenia of prematurity in neonates. Journal of Pioneering Medical Sciences2016;6(3):84-88. [LINK: www.jpmsonline.com/jpms-vol6-issue3-pages84-88-oa-text-only-file-2/]">Gharehbaghi 2016</a>; <a href="./references#CD015462-bbs2-0012" title="ScanlonJE , ChinKC , MorganME , DurbinGM , HaleKA , BrownSS . Caffeine or theophylline for neonatal apnoea?Archives of Disease in Childhood1992;67(4 Spec No):425-8. [DOI: 10.1136/adc.67.4_spec_no.425] [PMID: 1586184]">Scanlon 1992</a>; <a href="./references#CD015462-bbs2-0013" title="SchellackN , GousAGS , MawelaPB . Caffeine versus aminophylline for the prevention of apnoea of prematurity in a teaching hospital in South Africa. South African Family Practice2015;57(3):140-5. [DOI: 10.1080/20786190.2014.983310] [EMBASE: L605278311]">Schellack 2015</a>; <a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>; <a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>; <a href="./references#CD015462-bbs2-0016" title="SimsME , RangasamyR , LeeS , ChungH , CohenJ , WaltherFJ . Comparative evaluation of caffeine and theophylline for weaning premature infants from the ventilator. American Journal of Perinatology Reports1989;6(1):72-5. [DOI: 10.1055/s-2007-999549] [PMID: 2642707]">Sims 1989</a>). In <a href="./references#CD015462-bbs2-0012" title="ScanlonJE , ChinKC , MorganME , DurbinGM , HaleKA , BrownSS . Caffeine or theophylline for neonatal apnoea?Archives of Disease in Childhood1992;67(4 Spec No):425-8. [DOI: 10.1136/adc.67.4_spec_no.425] [PMID: 1586184]">Scanlon 1992</a>, participants were divided into three groups: one group received standard doses of caffeine, one high doses of caffeine, and the third received theophylline. </p> </section> <section id="CD015462-sec-0046"> <h4 class="title">Excluded studies</h4> <p>Following full‐text screening, we excluded 12 studies: 5 because they were not randomized trials (<a href="./references#CD015462-bbs2-0027" title="DandurandKR . Use of caffeine in neonates. AmericanJournal of Hospital Pharmacy1984;41(8):1520-1. [PMID: 6475971]">Dandurand 1984</a>; <a href="./references#CD015462-bbs2-0028" title="KaminskySK , FisbergM . Metabolism of caffeine and apnea newborn infant. Revista Paulista de Pediatria1991;9(32):3-9. [LINK: pesquisa.bvsalud.org/portal/resource/pt/lil-101139]">Kaminsky 1991</a>; <a href="./references#CD015462-bbs2-0030" title="NagasatoA , NakamuraM , KamimuraH . Comparative study of the efficacy and safety of caffeine and aminophylline for the treatment of apnea in preterm infants. Yakugaku Zasshi. Journal of the Pharmaceutical Society of Japan2018;138(2):237-42. [DOI: 10.1248/yakushi.17-00144] [PMID: 29386437]">Nagasato 2018</a>; <a href="./references#CD015462-bbs2-0032" title="SpiererDN , KoyamaEA . Caffeine citrate: an alternative to theophylline for apnea in prematurity. Drug Intelligence &amp; Clinical Pharmacy1985;19(10):762-3. [DOI: 10.1177/106002808501901017] [PMID: 4053984]">Spierer 1985</a>; <a href="./references#CD015462-bbs2-0033" title="WakamatsuA , UmetsuM , MotoyaH , NakaoT . Change of plasma half-life of caffeine during caffeine therapy for apnea in premature infants. Acta Paediatrica Japonica1987;29(4):595-9. [PMID: 3144898]">Wakamatsu 1987</a>); 4 because they were not about caffeine (<a href="./references#CD015462-bbs2-0025" title="CottancinG , BaltassatP , BoryC , ChallamelMJ , FrederichA . Pharmacokinetics of theophylline in low birth weight newborn infants. Pediatrie1977;32(7):677-84. [PMID: 928035]">Cottancin 1977</a>; <a href="./references#CD015462-bbs2-0026" title="CottancinG , SannL , BoryB , BourgeoisJ , FrederichA , BaltassatP , et al. Apnea and theophylline in the premature infant. Clinical and pharmacokinetic study in 32 premature infants. Pediatrie1981;36(2):91-101. [PMID: 7232073]">Cottancin 1981</a>; <a href="./references#CD015462-bbs2-0031" title="ShannonDC , GotayF . Effects of theophylline on serum and urine electrolytes in preterm infants with apnea. Journal of Pediatrics1979;94(6):963-5. [DOI: 10.1016/s0022-3476(79)80235-8] [PMID: 448547]">Shannon 1979</a>; <a href="./references#CD015462-bbs2-0034" title="XiaoruiH . Intervention effect study point percussion therapy on apnea in premature infants [点穴疗法对早产儿呼吸暂停的干预效果研究]. Chinese Nursing Research2017;31(10):1181‐4. [DOI: 10.3969/j.issn.1009-6493.2017.10.009]">Xiaorui 2017</a>); and 3 because caffeine was not compared to other methylxanthines (<a href="./references#CD015462-bbs2-0023" title="ArmanianAM , IranpourR , FaghihianE , SalehimehrN . Caffeine administration to prevent apnea in very premature infants. Pediatrics and Neonatology2016;57(5):408-12. [DOI: 10.1016/j.pedneo.2015.10.007] [PMID: 26976495]">Armanian 2016</a>; <a href="./references#CD015462-bbs2-0024" title="BerthouF , AlixD , RicheC , PicartD , DreanoY , GouedardH . Use of caffeine in the treatment of apnea in premature infants. Developmental Pharmacology and Therapeutics1982;4 Suppl:187-96. [PMID: 7128389]">Berthou 1982</a>; <a href="./references#CD015462-bbs2-0029" title="MuratI , MorietteG , BlinMC , CouchardM , FlouvatB , De GamarraE , et al. The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. Journal of Pediatrics1982;99(6):984-9. [DOI: 10.1016/s0022-3476(81)80038-8] [PMID: 7310594]">Murat 1982</a>). See <a href="./references#CD015462-sec-0124" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD015462-sec-0047"> <h4 class="title">Studies awaiting classification</h4> <p>We report one study as awaiting classification; neither an abstract nor full‐text publication are available (<a href="./references#CD015462-bbs2-0035" title="BairamA , BoutroyMJ , BadonnelY , VertP . Theophylline (T) vs caffeine (C) in the treatment of apnea in preterm infants. Pediatric Research1986;20:342. ">Bairam 1986</a>; <a href="./references#CD015462-sec-0125" title="">Characteristics of studies awaiting classification</a>). </p> </section> <section id="CD015462-sec-0048"> <h4 class="title">Ongoing studies</h4> <p>We identified four ongoing studies (<a href="./references#CD015462-bbs2-0036" title="CTRI/2015/06/005904. Setting of appropriate dosage and comparing the effectiveness of caffeine and aminophylline in premature babies with pause of breathing for 15 to 20 seconds [Population pharmacokinetic and pharmacodynamic study of aminophylline and caffeine in premature newborns with Apnea]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2015/06/005904 (first received 10 June 2015). [CENTRAL: CN-01884087] ">CTRI/2015/06/005904</a>; <a href="./references#CD015462-bbs2-0037" title="CTRI/2018/05/014329. Study to compare caffeine and aminophylline in the management of apnea of prematurity [Comparative study to evaluate efficacy and adverse effects of caffeine and aminophylline in the management of apnea of prematurity]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2018/05/014329 (first received 31 May 2018). [CENTRAL: CN-01905078] ">CTRI/2018/05/014329</a>; <a href="./references#CD015462-bbs2-0038" title="DRKS00020404. Comparing the prophylactic effects of caffeine versus aminophylline on the apnea in premature neonates of Kabul city: a randomized clinical trial. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00020404 (first received 16 March 2020). [CENTRAL: CN-02168784] ">DRKS00020404</a>; <a href="./references#CD015462-bbs2-0039" title="IRCT20181110041605N. Comparison of effectiveness of caffeine with aminophylline in treatment of prematurity apnea in preterm [Comparison of the effect of caffeine with aminophylline in treatment of prematurity apnea in preterm neonate (&lt;34 weeks) that admitted in NICU]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20181110041605N1 (first received 6 March 2019). [CENTRAL: CN-01950347] ">IRCT20181110041605N</a>). See <a href="./references#CD015462-sec-0126" title="">Characteristics of ongoing studies</a>. </p> <p><a href="./references#CD015462-bbs2-0036" title="CTRI/2015/06/005904. Setting of appropriate dosage and comparing the effectiveness of caffeine and aminophylline in premature babies with pause of breathing for 15 to 20 seconds [Population pharmacokinetic and pharmacodynamic study of aminophylline and caffeine in premature newborns with Apnea]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2015/06/005904 (first received 10 June 2015). [CENTRAL: CN-01884087] ">CTRI/2015/06/005904</a> investigates premature infants with apnea: the aim of the trial is to set the appropriate dosage and compare the effectiveness of caffeine and aminophylline to reduce episodes of apnea. The study is being conducted in India, and the planned sample size is 402 newborns. </p> <p><a href="./references#CD015462-bbs2-0037" title="CTRI/2018/05/014329. Study to compare caffeine and aminophylline in the management of apnea of prematurity [Comparative study to evaluate efficacy and adverse effects of caffeine and aminophylline in the management of apnea of prematurity]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2018/05/014329 (first received 31 May 2018). [CENTRAL: CN-01905078] ">CTRI/2018/05/014329</a> investigates the efficacy of caffeine and aminophylline in the management of apnea of prematurity and long term effects of methylxanthines (e.g. neurodevelopmental outcome at one year of age). The enrollment is being conducted in India with a target sample size of 100 participants. </p> <p><a href="./references#CD015462-bbs2-0038" title="DRKS00020404. Comparing the prophylactic effects of caffeine versus aminophylline on the apnea in premature neonates of Kabul city: a randomized clinical trial. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00020404 (first received 16 March 2020). [CENTRAL: CN-02168784] ">DRKS00020404</a> compares the effects of caffeine and theophylline for prevention of apnea of prematurity. The trial is being conducted in Afghanistan with a target sample size of 80 infants. </p> <p><a href="./references#CD015462-bbs2-0039" title="IRCT20181110041605N. Comparison of effectiveness of caffeine with aminophylline in treatment of prematurity apnea in preterm [Comparison of the effect of caffeine with aminophylline in treatment of prematurity apnea in preterm neonate (&lt;34 weeks) that admitted in NICU]. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20181110041605N1 (first received 6 March 2019). [CENTRAL: CN-01950347] ">IRCT20181110041605N</a> investigates premature babies born at less than 34 weeks of gestational age to assess efficacy of caffeine and theophylline for apnea of prematurity. The study is being conducted in Iran, with a planned sample size of 80 infants. </p> </section> </section> <section id="CD015462-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall risk of bias assessment is shown in <a href="#CD015462-fig-0002">Figure 2</a> and <a href="#CD015462-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD015462-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD015462-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD015462-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD015462-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD015462-sec-0050"> <h4 class="title">Allocation</h4> <p>Most included studies did not report how a random sequence was generated, and how allocation was concealed, and therefore received a judgment of an unclear risk of bias. Six studies reported how a random sequence was generated (<a href="./references#CD015462-bbs2-0004" title="FangS , SherwoodRA , GamsuHR , MarsdenJT , PetersTJ , GreenoughA . Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. European Journal of Pediatrics1998;157(5):406-9. [DOI: 10.1007/s004310050840] [PMID: 9625339]">Fang 1998</a>; <a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>; <a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>; <a href="./references#CD015462-bbs2-0016" title="SimsME , RangasamyR , LeeS , ChungH , CohenJ , WaltherFJ . Comparative evaluation of caffeine and theophylline for weaning premature infants from the ventilator. American Journal of Perinatology Reports1989;6(1):72-5. [DOI: 10.1055/s-2007-999549] [PMID: 2642707]">Sims 1989</a>; <a href="./references#CD015462-bbs2-0017" title="SkouroliakouM , BacopoulouF , MarkantonisSL . Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. Journal of Paediatrics and Child Health2009;45(10):587-92. [DOI: 10.1111/j.1440-1754.2009.01570.x] [PMID: 19751376]">Skouroliakou 2009</a>; <a href="./references#CD015462-bbs2-0019" title="YangD , ZhouB , JinB , LiuX , WangY . Amplitude integrated electroencephalogram study of the effect of caffeine citrate on brain development in low weight infants with apnea. Iranian Journal of Public Health2019;48(7):1278-83. [PMID: 31497549]">Yang 2019</a>); all of these received a low risk of bias rating. In five studies, the randomization code was computer‐generated, and in one study, randomization was generated using the random number table method (<a href="./references#CD015462-bbs2-0019" title="YangD , ZhouB , JinB , LiuX , WangY . Amplitude integrated electroencephalogram study of the effect of caffeine citrate on brain development in low weight infants with apnea. Iranian Journal of Public Health2019;48(7):1278-83. [PMID: 31497549]">Yang 2019</a>). Five studies reported how allocation was concealed and received a judgment of low risk of bias (<a href="./references#CD015462-bbs2-0012" title="ScanlonJE , ChinKC , MorganME , DurbinGM , HaleKA , BrownSS . Caffeine or theophylline for neonatal apnoea?Archives of Disease in Childhood1992;67(4 Spec No):425-8. [DOI: 10.1136/adc.67.4_spec_no.425] [PMID: 1586184]">Scanlon 1992</a>; <a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>; <a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>; <a href="./references#CD015462-bbs2-0017" title="SkouroliakouM , BacopoulouF , MarkantonisSL . Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. Journal of Paediatrics and Child Health2009;45(10):587-92. [DOI: 10.1111/j.1440-1754.2009.01570.x] [PMID: 19751376]">Skouroliakou 2009</a>; <a href="./references#CD015462-bbs2-0022" title="ZulqarnainA , HussainM , SuleriKM , Ali ChZ . Comparison of caffeine versus theophylline for apnea of prematurity. Pakistan Journal of Medical Sciences2019;35(1):113-6. [DOI: 10.12669/pjms.35.1.94] [PMID: 30881407]">Zulqarnain 2019</a>). </p> </section> <section id="CD015462-sec-0051"> <h4 class="title">Blinding</h4> <p>In most of the included studies, other methylxanthines were given more often than caffeine. We assumed therefore that the personnel could not be blinded, and these studies received a high risk of bias rating for the blinding of participants and personnel domain. The <a href="./references#CD015462-bbs2-0011" title="LundstrømKE , LarsenPB , BrendstrupL , SkovL , GreisenG . Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or aminophylline. Acta Paediatrica, International Journal of Paediatrics1995;84(1):6-9. [DOI: 10.1111/j.1651-2227.1995.tb13474.x] [PMID: 7734901]">Lundstrøm 1995</a> study received an unclear risk of bias in this domain since trialists measured their outcomes after the loading dose, but it was not specified if the personnel giving this dose were blinded. </p> <p>Three studies received a low risk of bias assessment for blinding of participants and personnel (<a href="./references#CD015462-bbs2-0001" title="BairamA , BoutroyMJ , BadonnelY , VertP . The choice between theophylline and caffeine in the treatment of apneas of prematurity. Archives Francaises de Pediatrie1990;47(6):461-5. [PMID: 2206108]BairamA , BoutroyMJ , BadonnelY , VertP . Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. Journal of Pediatrics1987;110(4):636-9. [DOI: 10.1016/s0022-3476(87)80569-3] [PMID: 3559816]">Bairam 1987</a>; <a href="./references#CD015462-bbs2-0005" title="FuglsangG , NielsenK , Kjaer NielsenL , SennelsF , JakobsenP , ThelleT . The effect of caffeine compared with theophylline in the treatment of idiopathic apnea in premature infants. Acta Paediatrica1989;78(5):786-8. [DOI: 10.1111/j.1651-2227.1989.tb11147.x] [PMID: 2688355]">Fuglsang 1989</a>; <a href="./references#CD015462-bbs2-0016" title="SimsME , RangasamyR , LeeS , ChungH , CohenJ , WaltherFJ . Comparative evaluation of caffeine and theophylline for weaning premature infants from the ventilator. American Journal of Perinatology Reports1989;6(1):72-5. [DOI: 10.1055/s-2007-999549] [PMID: 2642707]">Sims 1989</a>). These studies reported their methods for blinding personnel; for example, by giving the caffeine group placebo to ensure that both groups received drugs the same number of times per day. </p> <p>For outcome assessment, most studies received an unclear risk of bias rating, and we judged no studies as having a high risk of bias. Five studies received a low risk of bias rating since they reported how blinding of outcome assessment was achieved (<a href="./references#CD015462-bbs2-0004" title="FangS , SherwoodRA , GamsuHR , MarsdenJT , PetersTJ , GreenoughA . Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. European Journal of Pediatrics1998;157(5):406-9. [DOI: 10.1007/s004310050840] [PMID: 9625339]">Fang 1998</a>; <a href="./references#CD015462-bbs2-0006" title="GharehbaghiMM , TaheriM , GharabaghiF . Comparing the effect of caffeine and aminophylline on the osteopenia of prematurity in neonates. Journal of Pioneering Medical Sciences2016;6(3):84-88. [LINK: www.jpmsonline.com/jpms-vol6-issue3-pages84-88-oa-text-only-file-2/]">Gharehbaghi 2016</a>; <a href="./references#CD015462-bbs2-0007" title="HabibiM , MahyarA , NikdehghanS . Effect of caffeine and aminophylline on apnea of prematurity. Iranian Journal of Neonatology2019;10(2):37-41. [DOI: 10.22038/ijn.2019.33041.1468] [EMBASE: L2002904738]">Habibi 2019</a>; <a href="./references#CD015462-bbs2-0017" title="SkouroliakouM , BacopoulouF , MarkantonisSL . Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. Journal of Paediatrics and Child Health2009;45(10):587-92. [DOI: 10.1111/j.1440-1754.2009.01570.x] [PMID: 19751376]">Skouroliakou 2009</a>; <a href="./references#CD015462-bbs2-0022" title="ZulqarnainA , HussainM , SuleriKM , Ali ChZ . Comparison of caffeine versus theophylline for apnea of prematurity. Pakistan Journal of Medical Sciences2019;35(1):113-6. [DOI: 10.12669/pjms.35.1.94] [PMID: 30881407]">Zulqarnain 2019</a>). </p> </section> <section id="CD015462-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>Most included studies reported outcome data for all randomized infants. Four studies received an unclear risk of bias rating for the following reasons. </p> <p> <ul id="CD015462-list-0016"> <li> <p>In <a href="./references#CD015462-bbs2-0006" title="GharehbaghiMM , TaheriM , GharabaghiF . Comparing the effect of caffeine and aminophylline on the osteopenia of prematurity in neonates. Journal of Pioneering Medical Sciences2016;6(3):84-88. [LINK: www.jpmsonline.com/jpms-vol6-issue3-pages84-88-oa-text-only-file-2/]">Gharehbaghi 2016</a>, 26 infants were excluded because of death or discharge and outcomes were therefore not reported for those infants. It was not specified to which intervention the excluded infants were randomized. </p> </li> <li> <p>For <a href="./references#CD015462-bbs2-0008" title="KumarSP , MehtaPN , BradleyBS , EzhuthachanSG . Documented monitoring (DM) shows theophylline (T) to be more effective than caffeine (C) in prematurity apnea (PA). Pediatric Research1992;31:208A. ">Kumar 1992</a>, we did not have the full text. </p> </li> <li> <p>In <a href="./references#CD015462-bbs2-0009" title="LarsenPB , BrendstrupL , SkovL , FlachsH . Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. Acta Paediatrica1995;84(4):360-4. [DOI: 10.1111/j.1651-2227.1995.tb13649.x] [PMID: 7795341]">Larsen 1995</a>, it was not clear how many infants from each intervention completed the protocol. </p> </li> <li> <p>The <a href="./references#CD015462-bbs2-0010" title="LaubscherB , GreenoughA , DimitriouG . Comparative effects of theophylline and caffeine on respiratory function of prematurely born infants. Early Human Development1998;50(2):185-92. [DOI: 10.1016/s0378-3732(97)00038-6] [PMID: 9483391]">Laubscher 1998</a> authors do not report to which group excluded infants belonged. </p> </li> </ul> </p> </section> <section id="CD015462-sec-0053"> <h4 class="title">Selective reporting</h4> <p>The study protocol was only available for two studies (<a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>; <a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>). Both of these studies included outcomes that were not reported in the protocol, and therefore received a high risk of bias rating. For the remaining 20 studies, we judged the risk of reporting bias as unclear because study protocols were not available. </p> </section> <section id="CD015462-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p>We found no other potential sources of bias in the included studies.</p> </section> </section> <section id="CD015462-sec-0055"> <h3 class="title" id="CD015462-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD015462-tbl-0001"><b>Summary of findings 1</b> Caffeine compared to other methylxanthines for the prevention and treatment of apnea in preterm infants</a> </p> <section id="CD015462-sec-0056"> <h4 class="title">Caffeine versus either aminophylline or theophylline</h4> <p>See <a href="./full#CD015462-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD015462-sec-0057"> <h5 class="title">Primary outcomes</h5> <section id="CD015462-sec-0058"> <h6 class="title">All‐cause mortality prior to hospital discharge (any setting)</h6> <p>Four studies reported this outcome (<a href="./references#CD015462-bbs2-0010" title="LaubscherB , GreenoughA , DimitriouG . Comparative effects of theophylline and caffeine on respiratory function of prematurely born infants. Early Human Development1998;50(2):185-92. [DOI: 10.1016/s0378-3732(97)00038-6] [PMID: 9483391]">Laubscher 1998</a>; <a href="./references#CD015462-bbs2-0013" title="SchellackN , GousAGS , MawelaPB . Caffeine versus aminophylline for the prevention of apnoea of prematurity in a teaching hospital in South Africa. South African Family Practice2015;57(3):140-5. [DOI: 10.1080/20786190.2014.983310] [EMBASE: L605278311]">Schellack 2015</a>; <a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>; <a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>). One infant out of 45 infants died in one study; the study could not be pooled in the meta‐analysis because it did not report if the death was in the caffeine or control group (<a href="./references#CD015462-bbs2-0010" title="LaubscherB , GreenoughA , DimitriouG . Comparative effects of theophylline and caffeine on respiratory function of prematurely born infants. Early Human Development1998;50(2):185-92. [DOI: 10.1016/s0378-3732(97)00038-6] [PMID: 9483391]">Laubscher 1998</a>). One study reported this outcome but with different numbers in the text versus the table; thus, it could not be pooled in the meta‐analysis (<a href="./references#CD015462-bbs2-0013" title="SchellackN , GousAGS , MawelaPB . Caffeine versus aminophylline for the prevention of apnoea of prematurity in a teaching hospital in South Africa. South African Family Practice2015;57(3):140-5. [DOI: 10.1080/20786190.2014.983310] [EMBASE: L605278311]">Schellack 2015</a>). </p> <p>Caffeine administrated for any indication may result in little to no difference in all‐cause mortality prior to hospital discharge compared to other methylxanthines (RR 1.12, 95% CI 0.68 to 1.84; RD 0.02, 95% CI ‐0.05 to 0.08; I<sup>2</sup> = 0 for RR and RD; 2 studies, 396 infants; low‐certainty evidence; <a href="./references#CD015462-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD015462-sec-0059"> <h6 class="title">Moderate to severe neurodevelopmental disability at 18 to 26 months</h6> <p>No studies reported this composite outcome.</p> <section id="CD015462-sec-0060"> <p><b>Components of the composite outcome 'major neurodevelopmental disability'</b></p> <p> <ul id="CD015462-list-0017"> <li> <p><b>Cerebral palsy</b>: no studies reported this outcome. </p> </li> <li> <p><b>Gross motor disability</b> (defined as ≥ level 2 according to the Gross Motor Function Classification System (GMFCS)): no studies reported this outcome. </p> </li> <li> <p><b>Developmental delay</b> more than two SDs below population mean on a standardized test of development: one study reported this outcome (<a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>). Cognitive, language, and motor delay were defined as a score of less than 85 on the Bayley Scale of Infant and toddler Development (BSID‐III). </p> <ul id="CD015462-list-0018"> <li> <p><b><i>Cognitive:</i> </b> the evidence is very uncertain about the effect of caffeine on cognitive developmental delay compared to other methylxanthines (RR 0.17, 95% CI 0.02 to 1.37; RD ‐0.12, 95% CI ‐0.24 to 0.01; I<sup>2</sup> not applicable; 1 study, 79 infants; very low‐certainty evidence; <a href="./references#CD015462-fig-0005" title="">Analysis 1.2</a>). </p> </li> <li> <p><b><i>Language</i> </b>: the evidence is very uncertain about the effect of caffeine on language developmental delay compared to other methylxanthines (RR 0.76, 95% CI 0.37 to 1.58; RD ‐0.07, 95% CI ‐0.27 to 0.12; I<sup>2</sup> not applicable; 1 study, 79 infants; very low‐certainty evidence; <a href="./references#CD015462-fig-0006" title="">Analysis 1.3</a>). </p> </li> <li> <p><b><i>Motor</i> </b>: the evidence is very uncertain about the effect of caffeine on motor developmental delay compared to other methylxanthines (RR 0.50, 95% CI 0.13 to 1.96; RD ‐0.07, 95% CI ‐0.21 to 0.07; I<sup>2</sup> not applicable; 1 study, 79 infants; very low‐certainty evidence; <a href="./references#CD015462-fig-0007" title="">Analysis 1.4</a>). </p> </li> </ul> </li> <li> <p><b><i>Mental development</i> </b> (IQ) &gt; 2 SD below the mean: no studies reported this outcome. </p> </li> <li> <p><b><i>Visual impairment</i> </b>(vision &lt; 6/60 in both eyes): one study reported this outcome (<a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>). This outcome was reported only for those infants with a retinopathy of prematurity (ROP) diagnosis at discharge. At 24 months of age, visual impairment was seen in 8 out of 11 and 10 out of 11 infants in the caffeine and other methylxanthines group, respectively. The evidence is very uncertain about the effect of caffeine on visual impairment compared to other methylxanthines. </p> </li> <li> <p><b><i>Hearing impairment</i> </b> (requiring amplification): one study reported this outcome (<a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>). This outcome was reported only for those infants with abnormal hearing screening prior to discharge using auditory brain stem evoked response (ABR) and otoacoustic emission (OAE). At 24 months of age, hearing impairment was seen in 2 out of 5 infants and 1 out of 1 infant in the caffeine and other methylxanthines group, respectively. The evidence is very uncertain about the effect of caffeine on hearing impairment compared to other methylxanthines. </p> </li> </ul> </p> </section> </section> </section> <section id="CD015462-sec-0061"> <h5 class="title">Secondary outcomes</h5> <section id="CD015462-sec-0062"> <h6 class="title">BPD/chronic lung disease: defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age; and using the 'physiological definition' </h6> <p>Three studies reported this outcome (<a href="./references#CD015462-bbs2-0006" title="GharehbaghiMM , TaheriM , GharabaghiF . Comparing the effect of caffeine and aminophylline on the osteopenia of prematurity in neonates. Journal of Pioneering Medical Sciences2016;6(3):84-88. [LINK: www.jpmsonline.com/jpms-vol6-issue3-pages84-88-oa-text-only-file-2/]">Gharehbaghi 2016</a>; <a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>; <a href="./references#CD015462-bbs2-0018" title="XiangS , LiuD , MaY , ZhangN , LiH , DuX , et al. The effect of cpap combined with caffeine citrate on apnea of prematurity. International Journal of Clinical and Experimental Medicine2021;14(1):639-45. [EMBASE: L2005953778]">Xiang 2021</a>). Caffeine may result in little to no difference in BPD/chronic lung disease compared to other methylxanthines (RR 1.40, 95% CI 0.92 to 2.11; RD 0.04, 95% CI ‐0.01 to 0.09; I<sup>2</sup> = 27% for RR and 86% for RD; 3 studies, 481 infants; low‐certainty evidence; <a href="./references#CD015462-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD015462-sec-0063"> <h6 class="title">Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines </h6> <p>One study reported this outcome (<a href="./references#CD015462-bbs2-0012" title="ScanlonJE , ChinKC , MorganME , DurbinGM , HaleKA , BrownSS . Caffeine or theophylline for neonatal apnoea?Archives of Disease in Childhood1992;67(4 Spec No):425-8. [DOI: 10.1136/adc.67.4_spec_no.425] [PMID: 1586184]">Scanlon 1992</a>). The evidence is very uncertain about the effect of caffeine on side effects (tachycardia, agitation, or feed intolerance) compared to other methylxanthines (RR 0.17, 95% CI 0.02 to 1.32; RD ‐0.29, 95% CI ‐0.57 to ‐0.02; I<sup>2</sup> not applicable; 1 study, 30 infants; very low‐certainty evidence; <a href="./references#CD015462-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD015462-sec-0064"> <h6 class="title">Duration of hospital stay</h6> <p>One study reported this outcome as median and IQR and therefore could not be pooled in a meta‐analysis: caffeine 43 days (IQR 27.5 to 61.5); other methylxanthines: 39 days (IQR 28 to 55) (<a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>). Caffeine may result in little to no difference in duration of hospital stay compared to other methylxanthines. </p> </section> <section id="CD015462-sec-0065"> <h6 class="title">Seizures (clinically diagnosed)</h6> <p>No studies reported this outcome.</p> </section> <section id="CD015462-sec-0066"> <h6 class="title">Failure to extubate within one week of commencing treatment</h6> <p>Three studies reported this outcome (<a href="./references#CD015462-bbs2-0016" title="SimsME , RangasamyR , LeeS , ChungH , CohenJ , WaltherFJ . Comparative evaluation of caffeine and theophylline for weaning premature infants from the ventilator. American Journal of Perinatology Reports1989;6(1):72-5. [DOI: 10.1055/s-2007-999549] [PMID: 2642707]">Sims 1989</a>; <a href="./references#CD015462-bbs2-0021" title="ZanardoV , DaniC , TrevisanutoD , MeneghettiS , GuglielmiA , ZacchelloG , et al. Methylxanthines increase renal calcium excretion in preterm infants. Biology of the Neonate1995;68(3):169-74. [DOI: 10.1159/000244234] [PMID: 8534781]">Zanardo 1995</a>; <a href="./references#CD015462-bbs2-0018" title="XiangS , LiuD , MaY , ZhangN , LiH , DuX , et al. The effect of cpap combined with caffeine citrate on apnea of prematurity. International Journal of Clinical and Experimental Medicine2021;14(1):639-45. [EMBASE: L2005953778]">Xiang 2021</a>). One study reported success rate of ventilator weaning but did not state when this outcome was measured; therefore, it could not be pooled in the meta‐analysis (<a href="./references#CD015462-bbs2-0018" title="XiangS , LiuD , MaY , ZhangN , LiH , DuX , et al. The effect of cpap combined with caffeine citrate on apnea of prematurity. International Journal of Clinical and Experimental Medicine2021;14(1):639-45. [EMBASE: L2005953778]">Xiang 2021</a>). The evidence is very uncertain about the effect of caffeine on failure to extubate within one week of commencing treatment compared to other methylxanthines (RR 0.75, 95% CI 0.14 to 3.90; RD ‐0.02, 95% CI ‐0.15 to 0.11; I<sup>2</sup> not applicable; 2 studies, 59 infants; very low‐certainty evidence; <a href="./references#CD015462-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD015462-sec-0067"> <h6 class="title">Reintubation within one week of commencing treatment</h6> <p>No studies reported this outcome</p> </section> <section id="CD015462-sec-0068"> <h6 class="title">Failed apnea reduction after two to seven days (less than 50% reduction in apnea), for infants treated for apnea </h6> <p>Four studies reported this outcome (<a href="./references#CD015462-bbs2-0001" title="BairamA , BoutroyMJ , BadonnelY , VertP . The choice between theophylline and caffeine in the treatment of apneas of prematurity. Archives Francaises de Pediatrie1990;47(6):461-5. [PMID: 2206108]BairamA , BoutroyMJ , BadonnelY , VertP . Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. Journal of Pediatrics1987;110(4):636-9. [DOI: 10.1016/s0022-3476(87)80569-3] [PMID: 3559816]">Bairam 1987</a>; <a href="./references#CD015462-bbs2-0002" title="BrouardC , MorietteG , MuratI , FlouvatB , PajotN , WaltiH , et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. American Journal of Diseases of Children1985;139(7):698-700. [DOI: 10.1001/archpedi.1985.02140090060028] [PMID: 4014092]">Brouard 1985</a>; <a href="./references#CD015462-bbs2-0005" title="FuglsangG , NielsenK , Kjaer NielsenL , SennelsF , JakobsenP , ThelleT . The effect of caffeine compared with theophylline in the treatment of idiopathic apnea in premature infants. Acta Paediatrica1989;78(5):786-8. [DOI: 10.1111/j.1651-2227.1989.tb11147.x] [PMID: 2688355]">Fuglsang 1989</a>; <a href="./references#CD015462-bbs2-0012" title="ScanlonJE , ChinKC , MorganME , DurbinGM , HaleKA , BrownSS . Caffeine or theophylline for neonatal apnoea?Archives of Disease in Childhood1992;67(4 Spec No):425-8. [DOI: 10.1136/adc.67.4_spec_no.425] [PMID: 1586184]">Scanlon 1992</a>). The evidence is very uncertain about the effect of caffeine on failed apnea reduction after two to seven days compared to other methylxanthines (RR 2.19, CI 95% 0.50 to 9.56; RD 0.06, 95% CI ‐0.07 to 0.19; I<sup>2</sup> for RR not applicable, I<sup>2</sup> for RD = 0%; 4 studies, 84 infants; very low‐certainty evidence; <a href="./references#CD015462-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD015462-sec-0069"> <h6 class="title">Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after 24 hours from commencing treatment, in a 24‐hour period </h6> <p>Five studies reported this outcome after 24 hours (<a href="./references#CD015462-bbs2-0001" title="BairamA , BoutroyMJ , BadonnelY , VertP . The choice between theophylline and caffeine in the treatment of apneas of prematurity. Archives Francaises de Pediatrie1990;47(6):461-5. [PMID: 2206108]BairamA , BoutroyMJ , BadonnelY , VertP . Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. Journal of Pediatrics1987;110(4):636-9. [DOI: 10.1016/s0022-3476(87)80569-3] [PMID: 3559816]">Bairam 1987</a>; <a href="./references#CD015462-bbs2-0002" title="BrouardC , MorietteG , MuratI , FlouvatB , PajotN , WaltiH , et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. American Journal of Diseases of Children1985;139(7):698-700. [DOI: 10.1001/archpedi.1985.02140090060028] [PMID: 4014092]">Brouard 1985</a>; <a href="./references#CD015462-bbs2-0005" title="FuglsangG , NielsenK , Kjaer NielsenL , SennelsF , JakobsenP , ThelleT . The effect of caffeine compared with theophylline in the treatment of idiopathic apnea in premature infants. Acta Paediatrica1989;78(5):786-8. [DOI: 10.1111/j.1651-2227.1989.tb11147.x] [PMID: 2688355]">Fuglsang 1989</a>; <a href="./references#CD015462-bbs2-0017" title="SkouroliakouM , BacopoulouF , MarkantonisSL . Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. Journal of Paediatrics and Child Health2009;45(10):587-92. [DOI: 10.1111/j.1440-1754.2009.01570.x] [PMID: 19751376]">Skouroliakou 2009</a>; <a href="./references#CD015462-bbs2-0022" title="ZulqarnainA , HussainM , SuleriKM , Ali ChZ . Comparison of caffeine versus theophylline for apnea of prematurity. Pakistan Journal of Medical Sciences2019;35(1):113-6. [DOI: 10.12669/pjms.35.1.94] [PMID: 30881407]">Zulqarnain 2019</a>). One study reported this outcome without SD and could not be pooled in the meta‐analysis (<a href="./references#CD015462-bbs2-0005" title="FuglsangG , NielsenK , Kjaer NielsenL , SennelsF , JakobsenP , ThelleT . The effect of caffeine compared with theophylline in the treatment of idiopathic apnea in premature infants. Acta Paediatrica1989;78(5):786-8. [DOI: 10.1111/j.1651-2227.1989.tb11147.x] [PMID: 2688355]">Fuglsang 1989</a>). Caffeine may reduce number of episodes of apnea over a 24‐hour period compared to other methylxanthines (MD ‐0.70, 95% CI ‐0.76 to ‐0.64; I<sup>2</sup> = 99%; 4 studies, 206 infants; low‐certainty evidence; <a href="./references#CD015462-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD015462-sec-0070"> <h6 class="title">Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after one week </h6> <p>Six studies reported this outcome after one week (<a href="./references#CD015462-bbs2-0001" title="BairamA , BoutroyMJ , BadonnelY , VertP . The choice between theophylline and caffeine in the treatment of apneas of prematurity. Archives Francaises de Pediatrie1990;47(6):461-5. [PMID: 2206108]BairamA , BoutroyMJ , BadonnelY , VertP . Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. Journal of Pediatrics1987;110(4):636-9. [DOI: 10.1016/s0022-3476(87)80569-3] [PMID: 3559816]">Bairam 1987</a>; <a href="./references#CD015462-bbs2-0002" title="BrouardC , MorietteG , MuratI , FlouvatB , PajotN , WaltiH , et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. American Journal of Diseases of Children1985;139(7):698-700. [DOI: 10.1001/archpedi.1985.02140090060028] [PMID: 4014092]">Brouard 1985</a>; <a href="./references#CD015462-bbs2-0009" title="LarsenPB , BrendstrupL , SkovL , FlachsH . Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. Acta Paediatrica1995;84(4):360-4. [DOI: 10.1111/j.1651-2227.1995.tb13649.x] [PMID: 7795341]">Larsen 1995</a>; <a href="./references#CD015462-bbs2-0017" title="SkouroliakouM , BacopoulouF , MarkantonisSL . Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. Journal of Paediatrics and Child Health2009;45(10):587-92. [DOI: 10.1111/j.1440-1754.2009.01570.x] [PMID: 19751376]">Skouroliakou 2009</a>; <a href="./references#CD015462-bbs2-0020" title="YuM , HuangJH , ZhuR , ZhangXZ , WuWY , WenXH . Effect of caffeine citrate on early pulmonary function in preterm infants with apnea. Zhongguo Dang Dai Er Ke Za Zhi2016;18(3):206-10. [DOI: 10.7499/j.issn.1008-8830.2016.03.003] [PMID: 26975815]">Yu 2016</a>; <a href="./references#CD015462-bbs2-0022" title="ZulqarnainA , HussainM , SuleriKM , Ali ChZ . Comparison of caffeine versus theophylline for apnea of prematurity. Pakistan Journal of Medical Sciences2019;35(1):113-6. [DOI: 10.12669/pjms.35.1.94] [PMID: 30881407]">Zulqarnain 2019</a>). One study reported this outcome without SD and could not be pooled in the meta‐analysis (<a href="./references#CD015462-bbs2-0009" title="LarsenPB , BrendstrupL , SkovL , FlachsH . Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. Acta Paediatrica1995;84(4):360-4. [DOI: 10.1111/j.1651-2227.1995.tb13649.x] [PMID: 7795341]">Larsen 1995</a>). Caffeine likely results in little to no difference in number of apnea episodes after one week compared to other methylxanthines (MD ‐0.10, 95% CI ‐0.14 to ‐0.07; I<sup>2</sup> = 41%; 5 studies, 246 infants; moderate‐certainty evidence; <a href="./references#CD015462-fig-0013" title="">Analysis 1.10</a>). </p> </section> <section id="CD015462-sec-0071"> <h6 class="title">Apnea: number of infants with at least one episode (defined as interruption of breathing for more than 20 seconds) after 24 hours of commencing treatment, in a 24‐hour period, and over one week </h6> <p>No studies reported this outcome after 24 hours.</p> <p>One study reported this outcome after one week (<a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>). Caffeine may result in little to no difference in number of infants with at least one apnea episode after 24 hours of commencing treatment after one week compared to other methylxanthines (RR 1.10, 95% CI 0.83 to 1.46; RD 0.05, 95% CI ‐0.10 to 0.21; I<sup>2</sup> not applicable; 1 study, 156 infants; low‐certainty evidence; <a href="./references#CD015462-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD015462-sec-0072"> <h6 class="title">Number of days of respiratory support (mechanical ventilation; CPAP; high‐flow nasal cannula; NIPPV) </h6> <p>Two studies reported this outcome (<a href="./references#CD015462-bbs2-0020" title="YuM , HuangJH , ZhuR , ZhangXZ , WuWY , WenXH . Effect of caffeine citrate on early pulmonary function in preterm infants with apnea. Zhongguo Dang Dai Er Ke Za Zhi2016;18(3):206-10. [DOI: 10.7499/j.issn.1008-8830.2016.03.003] [PMID: 26975815]">Yu 2016</a>; <a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>). One study reported the data as median (with 25th percentile and 75th percentile) and could not be pooled in the meta‐analysis (<a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>). The median in the caffeine group was 10 (4.5, 20), and in the aminophylline/theophylline group, it was 9 (4, 15). The evidence is very uncertain about the effect of caffeine on number of days of respiratory support compared to other methylxanthines (MD ‐1.10, 95% CI ‐1.81 to ‐0.39; I<sup>2</sup> not applicable; 1 study, 40 infants; very low‐certainty evidence; <a href="./references#CD015462-fig-0015" title="">Analysis 1.12</a>). </p> </section> <section id="CD015462-sec-0073"> <h6 class="title">Number of days of mechanical ventilation</h6> <p>No studies reported this outcome.</p> </section> <section id="CD015462-sec-0074"> <h6 class="title">Number of days of supplemental oxygen</h6> <p>Two studies reported this outcome (<a href="./references#CD015462-bbs2-0006" title="GharehbaghiMM , TaheriM , GharabaghiF . Comparing the effect of caffeine and aminophylline on the osteopenia of prematurity in neonates. Journal of Pioneering Medical Sciences2016;6(3):84-88. [LINK: www.jpmsonline.com/jpms-vol6-issue3-pages84-88-oa-text-only-file-2/]">Gharehbaghi 2016</a>; <a href="./references#CD015462-bbs2-0020" title="YuM , HuangJH , ZhuR , ZhangXZ , WuWY , WenXH . Effect of caffeine citrate on early pulmonary function in preterm infants with apnea. Zhongguo Dang Dai Er Ke Za Zhi2016;18(3):206-10. [DOI: 10.7499/j.issn.1008-8830.2016.03.003] [PMID: 26975815]">Yu 2016</a>). The evidence is very uncertain about the effect of caffeine on number of days of supplemental oxygen compared to other methylxanthines (MD ‐1.15, 95% CI ‐1.81 to ‐0.49; I<sup>2</sup> = 93%; 2 studies, 165 infants; very low‐certainty evidence; <a href="./references#CD015462-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD015462-sec-0075"> <h6 class="title">Need for mechanical ventilation (yes/no)</h6> <p>No studies reported this outcome.</p> </section> <section id="CD015462-sec-0076"> <h6 class="title">Need for non‐invasive respiratory support (CPAP, NIPPV, high‐flow nasal cannulae)</h6> <p>No studies reported this outcome.</p> </section> <section id="CD015462-sec-0077"> <h6 class="title">Neonatal mortality (up to 28 days)</h6> <p>No studies reported this outcome.</p> </section> <section id="CD015462-sec-0078"> <h6 class="title">Intraventricular hemorrhage on brain ultrasound (any; and severe [Papile grade 3 to 4]) </h6> <p>One study reported this outcome (<a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>). The evidence is very uncertain about the effect of caffeine on intraventricular hemorrhage on brain ultrasound (any; and severe) compared to other methylxanthines (RR 1.00, 95% CI 0.30 to 3.32; RD 0.00, 95% CI ‐0.08 to 0.08; I<sup>2</sup> not applicable; 1 study, 156 infants; very low‐certainty evidence; <a href="./references#CD015462-fig-0017" title="">Analysis 1.14</a>). </p> </section> <section id="CD015462-sec-0079"> <h6 class="title">Cerebellar hemorrhage on brain ultrasound (yes/no)</h6> <p>No studies reported this outcome.</p> </section> <section id="CD015462-sec-0080"> <h6 class="title">Periventricular leukomalacia</h6> <p>One study reported this outcome (<a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>). The evidence is very uncertain about the effect of caffeine on periventricular leukomalacia compared to other methylxanthines (RR 0.67, 95% CI 0.11 to 3.88; RD ‐0.01, 95% CI ‐0.07 to 0.04; I<sup>2</sup> not applicable; 1 study, 156 infants; very low‐certainty evidence; <a href="./references#CD015462-fig-0018" title="">Analysis 1.15</a>). </p> </section> <section id="CD015462-sec-0081"> <h6 class="title">Necrotizing enterocolitis (proven = Bell stage 2 or greater)</h6> <p>Two studies reported this outcome(<a href="./references#CD015462-bbs2-0001" title="BairamA , BoutroyMJ , BadonnelY , VertP . The choice between theophylline and caffeine in the treatment of apneas of prematurity. Archives Francaises de Pediatrie1990;47(6):461-5. [PMID: 2206108]BairamA , BoutroyMJ , BadonnelY , VertP . Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. Journal of Pediatrics1987;110(4):636-9. [DOI: 10.1016/s0022-3476(87)80569-3] [PMID: 3559816]">Bairam 1987</a>; <a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>). The evidence is very uncertain about the effect of caffeine on NEC compared to other methylxanthines (RR 0.28, 95% CI 0.09 to 0.88; RD ‐0.10, 95% CI ‐0.19 to ‐0.02; I<sup>2</sup> = 0 for RR and RD; 2 studies, 176 infants; very low‐certainty evidence; <a href="./references#CD015462-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD015462-sec-0082"> <h6 class="title">Patent ductus arteriosus requiring treatment (cyclo‐oxygenase inhibitors or surgical ligation) </h6> <p>Two studies reported this outcome (<a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>; <a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>). Caffeine may result in little to no difference in PDA requiring treatment compared to other methylxanthines (RR 0.79, 95% CI 0.46 to 1.36; RD ‐0.03, 95% CI ‐0.08 to 0.03; I<sup>2</sup> = 0% for RR and 35% for RD; 2 studies, 396 infants; low‐certainty evidence; <a href="./references#CD015462-fig-0020" title="">Analysis 1.17</a>). </p> </section> <section id="CD015462-sec-0083"> <h6 class="title">Retinopathy of prematurity (any ROP; and severe ROP [stage 3 or greater])</h6> <p>Two studies reported this outcome (<a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>; <a href="./references#CD015462-bbs2-0018" title="XiangS , LiuD , MaY , ZhangN , LiH , DuX , et al. The effect of cpap combined with caffeine citrate on apnea of prematurity. International Journal of Clinical and Experimental Medicine2021;14(1):639-45. [EMBASE: L2005953778]">Xiang 2021</a>). The evidence is very uncertain about the effect of caffeine on ROP (any ROP; and severe ROP) compared to other methylxanthines (RR 1.15, 95% CI 0.42 to 3.21; RD 0.01, 95% CI ‐0.03 to 0.05; I<sup>2</sup> = 43% for RR and 66% for RD; 2 studies, 356 infants; very low‐certainty evidence; <a href="./references#CD015462-fig-0021" title="">Analysis 1.18</a>). </p> </section> <section id="CD015462-sec-0084"> <h6 class="title">Cost of neonatal care</h6> <p>No studies reported this outcome.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015462-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015462-sec-0085"></div> <section id="CD015462-sec-0086"> <h3 class="title" id="CD015462-sec-0086">Summary of main results</h3> <p>The two primary outcomes for this review were mortality and neurodevelopmental disability at 18 to 26 months. The meta‐analysis for mortality shows that caffeine administrated for any indication may result in little to no difference in all‐cause mortality prior to hospital discharge compared to other methylxanthines. The outcome neurodevelopmental disability, which included six components, was reported in one study (<a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>). The evidence is very uncertain about the effect of caffeine on cognitive, language, and motor developmental delay, visual impairment, and hearing impairment compared to other methylxanthines. No studies reported cerebral palsy or gross motor disability. </p> <p>Caffeine may result in little to no difference in BPD compared to other methylxanthines. For side effects leading to a reduction in dose, the evidence is very uncertain. Caffeine may result in little to no difference in duration of hospital stay compared to other methylxanthines. None of the studies reported on seizures. </p> </section> <section id="CD015462-sec-0087"> <h3 class="title" id="CD015462-sec-0087">Overall completeness and applicability of evidence</h3> <p><b>Study design</b> </p> <p>All included studies were RCTs.</p> <p><b>Types of participants</b> <br/>In all 22 included studies, the infants had a mean gestational age between 28 and 32 weeks and a mean birth weight between 1000 and 1500 g, except for one study whose participants had a mean gestational age of more than 32 weeks (<a href="./references#CD015462-bbs2-0019" title="YangD , ZhouB , JinB , LiuX , WangY . Amplitude integrated electroencephalogram study of the effect of caffeine citrate on brain development in low weight infants with apnea. Iranian Journal of Public Health2019;48(7):1278-83. [PMID: 31497549]">Yang 2019</a>), and two studies in infants with a mean birth weight of 1500 g or more (<a href="./references#CD015462-bbs2-0019" title="YangD , ZhouB , JinB , LiuX , WangY . Amplitude integrated electroencephalogram study of the effect of caffeine citrate on brain development in low weight infants with apnea. Iranian Journal of Public Health2019;48(7):1278-83. [PMID: 31497549]">Yang 2019</a>; <a href="./references#CD015462-bbs2-0020" title="YuM , HuangJH , ZhuR , ZhangXZ , WuWY , WenXH . Effect of caffeine citrate on early pulmonary function in preterm infants with apnea. Zhongguo Dang Dai Er Ke Za Zhi2016;18(3):206-10. [DOI: 10.7499/j.issn.1008-8830.2016.03.003] [PMID: 26975815]">Yu 2016</a>). In all included studies, the participants matched the review's inclusion criteria, except for a few individual infants in the prevention trials who were born after 34 weeks. A few infants in the treatment trials were also born after 34 weeks; however, for the treatment trials, our inclusion criterion was infants born at less than 37 weeks' gestation with signs of apnea. Thus, the participants in the included studies were representative of the types of participants specified in our inclusion criteria. </p> <p><b>Intervention and comparison</b> </p> <p>In the protocol, we included two different comparisons: caffeine versus theophylline and caffeine versus aminophylline (<a href="./references#CD015462-bbs2-0111" title="MorescoL , MarquesKA , Ardiles-RuesjasS , SollR , BruschettiniM . Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. Cochrane Database of Systematic Reviews2023, Issue 3. Art. No: CD015462. [DOI: 10.1002/14651858.CD015462]">Moresco 2023</a>). However, in the review's results, we decided to collapse these into only one comparison of caffeine to other methylxanthines. We did this because of the difficulty in distinguishing between trials that administered aminophylline or theophylline. Some trials gave both drugs, some trials gave aminophylline to infants who received drugs intravenously and theophylline to infants who received drugs orally, and in some trials, it was unclear if aminophylline or theophylline was used. </p> <p>In the protocol, we planned to include any duration and dose of treatment (<a href="./references#CD015462-bbs2-0111" title="MorescoL , MarquesKA , Ardiles-RuesjasS , SollR , BruschettiniM . Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. Cochrane Database of Systematic Reviews2023, Issue 3. Art. No: CD015462. [DOI: 10.1002/14651858.CD015462]">Moresco 2023</a>). However, one study had three groups: two groups of infants received caffeine – one "high dose" and one "standard dose" – and one group received other methylxanthines (<a href="./references#CD015462-bbs2-0012" title="ScanlonJE , ChinKC , MorganME , DurbinGM , HaleKA , BrownSS . Caffeine or theophylline for neonatal apnoea?Archives of Disease in Childhood1992;67(4 Spec No):425-8. [DOI: 10.1136/adc.67.4_spec_no.425] [PMID: 1586184]">Scanlon 1992</a>). Since the high dose was more than double the dose of any other study, we did not include this study group in our meta‐analysis. </p> <p>In the <a href="./references#CD015462-sec-0123" title="">Characteristics of included studies</a>, we reported the comparison intervention as theophylline or aminophylline, as the authors did. We are aware, however, that some authors described theophylline as 'given iv' (i.e. given intravenously), which means that they most likely gave aminophylline. Also, some authors labeled a study group as an "aminophylline" group, while writing in the methods that they gave theophylline, or vice versa. </p> <p><b>Outcome measures</b> <br/>For mortality, there was no discrepancy between the definition in the protocol (<a href="./references#CD015462-bbs2-0111" title="MorescoL , MarquesKA , Ardiles-RuesjasS , SollR , BruschettiniM . Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. Cochrane Database of Systematic Reviews2023, Issue 3. Art. No: CD015462. [DOI: 10.1002/14651858.CD015462]">Moresco 2023</a>), and studies that reported this outcome. For the component 'developmental delay' in the outcome 'neurodevelopmental disability', the prespecified definition was "developmental delay more than two SDs below population mean on a standardized test of development (including assessment with Bayley or Griffith scales) (<a href="./references#CD015462-bbs2-0047" title="BayleyN . Bayley Scales of Infant Development–II. San Antonio (TX): Psychological Corporation, 1993.">Bayley 1993</a>; <a href="./references#CD015462-bbs2-0048" title="BayleyN . Bayley Scales of Infant and Toddler Development. San Antonio (TX): Harcourt Assessment, 2005.">Bayley 2005</a>; <a href="./references#CD015462-bbs2-0067" title="GriffithsR . The Abilities of Babies: A Study of Mental Measurement. London (UK): University of London Press, 1954.">Griffiths 1954</a>)". However, in the study reporting this outcome, authors defined cognitive, language, and motor deficits by a score of less than 85 on BSID –III (<a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>). This was not completely in line with the protocol (<a href="./references#CD015462-bbs2-0111" title="MorescoL , MarquesKA , Ardiles-RuesjasS , SollR , BruschettiniM . Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. Cochrane Database of Systematic Reviews2023, Issue 3. Art. No: CD015462. [DOI: 10.1002/14651858.CD015462]">Moresco 2023</a>). Nevertheless, we decided to create an analysis for this outcome and describe this discrepancy with the protocol in a footnote (<a href="./references#CD015462-fig-0005" title="">Analysis 1.2</a>; <a href="./references#CD015462-fig-0006" title="">Analysis 1.3</a>; <a href="./references#CD015462-fig-0007" title="">Analysis 1.4</a>). For BPD, two studies used the same definition as our protocol (<a href="./references#CD015462-bbs2-0006" title="GharehbaghiMM , TaheriM , GharabaghiF . Comparing the effect of caffeine and aminophylline on the osteopenia of prematurity in neonates. Journal of Pioneering Medical Sciences2016;6(3):84-88. [LINK: www.jpmsonline.com/jpms-vol6-issue3-pages84-88-oa-text-only-file-2/]">Gharehbaghi 2016</a>; <a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>); one study did not provide a definition (<a href="./references#CD015462-bbs2-0018" title="XiangS , LiuD , MaY , ZhangN , LiH , DuX , et al. The effect of cpap combined with caffeine citrate on apnea of prematurity. International Journal of Clinical and Experimental Medicine2021;14(1):639-45. [EMBASE: L2005953778]">Xiang 2021</a>). For side effects, some studies reported side effects as tachycardia and feeding intolerance. However, only one study reported side effects that led to a reducton in dose or withholding of treatment, which was the outcome measure we planned to look at (<a href="./references#CD015462-bbs2-0012" title="ScanlonJE , ChinKC , MorganME , DurbinGM , HaleKA , BrownSS . Caffeine or theophylline for neonatal apnoea?Archives of Disease in Childhood1992;67(4 Spec No):425-8. [DOI: 10.1136/adc.67.4_spec_no.425] [PMID: 1586184]">Scanlon 1992</a>). Thus, we decided to only include the one study that reported side effects leading to an adjustment in dose or withholding of methylxanthines (<a href="./references#CD015462-bbs2-0012" title="ScanlonJE , ChinKC , MorganME , DurbinGM , HaleKA , BrownSS . Caffeine or theophylline for neonatal apnoea?Archives of Disease in Childhood1992;67(4 Spec No):425-8. [DOI: 10.1136/adc.67.4_spec_no.425] [PMID: 1586184]">Scanlon 1992</a>). One study reported duration of hospital stay in days; however, it was reported with median and IQR and not mean and SD (<a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>). </p> </section> <section id="CD015462-sec-0088"> <h3 class="title" id="CD015462-sec-0088">Certainty of the evidence</h3> <p><b>Study limitations</b><br/>In many of the studies, several risk of bias domains were unclear. When assessing whether to downgrade evidence certainty for study limitations, we took into consideration in which domains the risk of bias was high or unclear. For example, we considered blinding of outcome assessment to be more important for outcomes such as BPD and neurodevelopmental disability than for mortality, since the first two are more prone to a subjective evaluation and require the opinion of the clinician. </p> <p><b>Inconsistency</b><br/>For some outcomes, assessing for heterogeneity was not applicable when only one study was weighted in the meta‐analysis. The remaining outcomes had variable levels of heterogeneity, with I<sup>2</sup> ranging from 0% to 99%. Apart from I<sup>2</sup>, we also visually examined the forest plots and explored what happened with the I<sup>2</sup> statistic when low‐weighted studies were removed. Taking all of this together, we downgraded two analyses by two levels for very serious inconsistency (<a href="./references#CD015462-fig-0012" title="">Analysis 1.9</a>; <a href="./references#CD015462-fig-0016" title="">Analysis 1.13</a>). </p> <p><b>Indirectness</b><br/>In general, the included studies closely matched the eligibility criteria we specified, particularly for population, intervention, and comparison. For some outcomes, investigators measured the outcome at a different time point than what we specified in the protocol (<a href="./references#CD015462-bbs2-0111" title="MorescoL , MarquesKA , Ardiles-RuesjasS , SollR , BruschettiniM . Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. Cochrane Database of Systematic Reviews2023, Issue 3. Art. No: CD015462. [DOI: 10.1002/14651858.CD015462]">Moresco 2023</a>). However, we did not consider this clinically significant. The outcomes for moderate to severe neurodevelopmental disability at 18 to 26 months (cognitive, language, and motor) might have been downgraded for indirectness since they had a different definition of what counted as abnormal compared to our protocol (<a href="./references#CD015462-bbs2-0111" title="MorescoL , MarquesKA , Ardiles-RuesjasS , SollR , BruschettiniM . Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. Cochrane Database of Systematic Reviews2023, Issue 3. Art. No: CD015462. [DOI: 10.1002/14651858.CD015462]">Moresco 2023</a>). However, the certainty of evidence was already rated as very low for these outcomes and could not be further downgraded. Thus, we ultimately did not downgrade any outcomes for indirectness. </p> <p><b>Imprecision</b> <br/>Reasons to downgrade for imprecision were wide confidence intervals/interquartile ranges, few infants, and few events. We downgraded some outcomes two or three levels due to combinations of these factors. Most analyses were based on a relatively small number of infants and events. Many results had wide confidence intervals, sometimes including both the possibility that caffeine or other methylxanthines would be more effective. Thus, we downgraded several outcomes for this reason. </p> <p><b>Other considerations</b> <br/>We did not find any other reasons to downgrade evidence certainty. We did not suspect publication bias. </p> <p>See <a href="./full#CD015462-tbl-0001">summary of findings Table 1</a>. </p> </section> <section id="CD015462-sec-0089"> <h3 class="title" id="CD015462-sec-0089">Potential biases in the review process</h3> <p>During the protocol stage (<a href="./references#CD015462-bbs2-0111" title="MorescoL , MarquesKA , Ardiles-RuesjasS , SollR , BruschettiniM . Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. Cochrane Database of Systematic Reviews2023, Issue 3. Art. No: CD015462. [DOI: 10.1002/14651858.CD015462]">Moresco 2023</a>), we made subjective decisions. For example, we decided to use intention‐to‐treat analysis for all included outcomes. It is possible that choosing to look only at available data would have yielded different results. Deciding which outcomes to include is a very important decision, and potentially could be a source of bias. If we had chosen other outcomes, it is possible the results and conclusions from the review would be different. Likewise, all subjective decisions that were made during the protocol stage are potential sources of bias. </p> <p>For a detailed discussion of the differences between our protocol and this review, please see <a href="#CD015462-sec-0121">Differences between protocol and review</a>. </p> </section> <section id="CD015462-sec-0090"> <h3 class="title" id="CD015462-sec-0090">Agreements and disagreements with other studies or reviews</h3> <p>We found one previous review by <a href="./references#CD015462-bbs2-0069" title="Henderson‐SmartDJ , SteerPA . Caffeine versus theophylline for apnea in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD000273. [DOI: 10.1002/14651858.CD000273.pub2] [PMID: 20091506]">Henderson‐Smart 2010</a>, in the Cochrane Library, that compared caffeine to theophylline for apnea in preterm infants. That review found no differences in treatment failure rate and mean number of apneas after one to three days and after five to seven days of treatment between infants treated with caffeine compared to theophylline. Side effects leading to a reduction in dose were less frequent in the caffeine group. For treatment failure, this is similar to what we report in our review. For mean number of apneas after 24 hours of treatment, we identified a reduction in the number of apneas in infants treated with caffeine compared to other methylxanthines; this was not seen in the <a href="./references#CD015462-bbs2-0069" title="Henderson‐SmartDJ , SteerPA . Caffeine versus theophylline for apnea in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD000273. [DOI: 10.1002/14651858.CD000273.pub2] [PMID: 20091506]">Henderson‐Smart 2010</a> review. For side effects, our review included one study with few events, hence the certainty of evidence was too low to draw any conclusions. </p> <p>All included studies in the <a href="./references#CD015462-bbs2-0069" title="Henderson‐SmartDJ , SteerPA . Caffeine versus theophylline for apnea in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD000273. [DOI: 10.1002/14651858.CD000273.pub2] [PMID: 20091506]">Henderson‐Smart 2010</a> review were also included in our review, which could account for some similarities; any differences could be caused by the influence of an additional 17 studies included in our review (<a href="./references#CD015462-bbs2-0003" title="DaniC , BertiniG , RealiMF , TronchinM , WiechmannL , MartelliE , et al. Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment. Biology of the Neonate2000;78(1):27-32. [DOI: 10.1159/000014243] [PMID: 10878419]">Dani 2000</a>; <a href="./references#CD015462-bbs2-0004" title="FangS , SherwoodRA , GamsuHR , MarsdenJT , PetersTJ , GreenoughA . Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. European Journal of Pediatrics1998;157(5):406-9. [DOI: 10.1007/s004310050840] [PMID: 9625339]">Fang 1998</a>; <a href="./references#CD015462-bbs2-0006" title="GharehbaghiMM , TaheriM , GharabaghiF . Comparing the effect of caffeine and aminophylline on the osteopenia of prematurity in neonates. Journal of Pioneering Medical Sciences2016;6(3):84-88. [LINK: www.jpmsonline.com/jpms-vol6-issue3-pages84-88-oa-text-only-file-2/]">Gharehbaghi 2016</a>; <a href="./references#CD015462-bbs2-0007" title="HabibiM , MahyarA , NikdehghanS . Effect of caffeine and aminophylline on apnea of prematurity. Iranian Journal of Neonatology2019;10(2):37-41. [DOI: 10.22038/ijn.2019.33041.1468] [EMBASE: L2002904738]">Habibi 2019</a>; <a href="./references#CD015462-bbs2-0009" title="LarsenPB , BrendstrupL , SkovL , FlachsH . Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. Acta Paediatrica1995;84(4):360-4. [DOI: 10.1111/j.1651-2227.1995.tb13649.x] [PMID: 7795341]">Larsen 1995</a>; <a href="./references#CD015462-bbs2-0010" title="LaubscherB , GreenoughA , DimitriouG . Comparative effects of theophylline and caffeine on respiratory function of prematurely born infants. Early Human Development1998;50(2):185-92. [DOI: 10.1016/s0378-3732(97)00038-6] [PMID: 9483391]">Laubscher 1998</a>; <a href="./references#CD015462-bbs2-0011" title="LundstrømKE , LarsenPB , BrendstrupL , SkovL , GreisenG . Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or aminophylline. Acta Paediatrica, International Journal of Paediatrics1995;84(1):6-9. [DOI: 10.1111/j.1651-2227.1995.tb13474.x] [PMID: 7734901]">Lundstrøm 1995</a>; <a href="./references#CD015462-bbs2-0013" title="SchellackN , GousAGS , MawelaPB . Caffeine versus aminophylline for the prevention of apnoea of prematurity in a teaching hospital in South Africa. South African Family Practice2015;57(3):140-5. [DOI: 10.1080/20786190.2014.983310] [EMBASE: L605278311]">Schellack 2015</a>; <a href="./references#CD015462-bbs2-0014" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs,caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). KhuranaS , ShivakumarM , Sujith Kumar ReddyGV , JayashreeP , Ramesh BhatY , LewisLE . Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine2017;10(4):355-62. [DOI: 10.3233/NPM-16147] [PMID: 29286928]ShivakumarM , JayashreeP , NajihM , LewisLE , BhatYR , KamathA , et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. Indian Pediatrics2017;54(4):279-83. [PMID: 10.1007/s13312-017-1088-0] [PMID: 28474588]">Shivakumar 2017a</a>; <a href="./references#CD015462-bbs2-0015" title="CTRI/2012/08/002904. A clinical trial to study the effect of two drugs, caffeine &amp; aminophylline in preterm babies with cessation of breathing due to prematurity. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/08/002904 (first received 22 August 2012). ShivakumarM , NajihM , BhatYR , JayashreeP , LewisLE , KamathA , et al. Prophylactic methylxanthines for preventing extubation failure in the preterm neonates with the gestational age of ≤30 weeks: a randomized controlled trial. Iranian Journal of Neonatology2017;8(3):11-18. [DOI: 10.22038/ijn.2017.23031.1281] [EMBASE: L618446599]ShivakumarM , NayakK , LewisLE , KamathA , PurkayasthaJ . Acute hemodynamic effects of methylxanthine therapy in preterm neonates: effect of variations in subgroups. Journal of Tropical Pediatrics2019;65(3):264-72. [DOI: 10.1093/tropej/fmy044] [PMID: 30085175]">Shivakumar 2017b</a>; <a href="./references#CD015462-bbs2-0016" title="SimsME , RangasamyR , LeeS , ChungH , CohenJ , WaltherFJ . Comparative evaluation of caffeine and theophylline for weaning premature infants from the ventilator. American Journal of Perinatology Reports1989;6(1):72-5. [DOI: 10.1055/s-2007-999549] [PMID: 2642707]">Sims 1989</a>; <a href="./references#CD015462-bbs2-0017" title="SkouroliakouM , BacopoulouF , MarkantonisSL . Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. Journal of Paediatrics and Child Health2009;45(10):587-92. [DOI: 10.1111/j.1440-1754.2009.01570.x] [PMID: 19751376]">Skouroliakou 2009</a>; <a href="./references#CD015462-bbs2-0018" title="XiangS , LiuD , MaY , ZhangN , LiH , DuX , et al. The effect of cpap combined with caffeine citrate on apnea of prematurity. International Journal of Clinical and Experimental Medicine2021;14(1):639-45. [EMBASE: L2005953778]">Xiang 2021</a>; <a href="./references#CD015462-bbs2-0019" title="YangD , ZhouB , JinB , LiuX , WangY . Amplitude integrated electroencephalogram study of the effect of caffeine citrate on brain development in low weight infants with apnea. Iranian Journal of Public Health2019;48(7):1278-83. [PMID: 31497549]">Yang 2019</a>; <a href="./references#CD015462-bbs2-0020" title="YuM , HuangJH , ZhuR , ZhangXZ , WuWY , WenXH . Effect of caffeine citrate on early pulmonary function in preterm infants with apnea. Zhongguo Dang Dai Er Ke Za Zhi2016;18(3):206-10. [DOI: 10.7499/j.issn.1008-8830.2016.03.003] [PMID: 26975815]">Yu 2016</a>; <a href="./references#CD015462-bbs2-0021" title="ZanardoV , DaniC , TrevisanutoD , MeneghettiS , GuglielmiA , ZacchelloG , et al. Methylxanthines increase renal calcium excretion in preterm infants. Biology of the Neonate1995;68(3):169-74. [DOI: 10.1159/000244234] [PMID: 8534781]">Zanardo 1995</a>; <a href="./references#CD015462-bbs2-0022" title="ZulqarnainA , HussainM , SuleriKM , Ali ChZ . Comparison of caffeine versus theophylline for apnea of prematurity. Pakistan Journal of Medical Sciences2019;35(1):113-6. [DOI: 10.12669/pjms.35.1.94] [PMID: 30881407]">Zulqarnain 2019</a>). Any differences could also be caused by different interpretations of the data in the included studies. For example, the <a href="./references#CD015462-bbs2-0069" title="Henderson‐SmartDJ , SteerPA . Caffeine versus theophylline for apnea in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD000273. [DOI: 10.1002/14651858.CD000273.pub2] [PMID: 20091506]">Henderson‐Smart 2010</a> review included two studies in the analysis for two side effects (tachycardia and feed intolerance) that we chose not to include since we thought it was unclear if the side effects reported led to a reduction in dose or not (<a href="./references#CD015462-bbs2-0001" title="BairamA , BoutroyMJ , BadonnelY , VertP . The choice between theophylline and caffeine in the treatment of apneas of prematurity. Archives Francaises de Pediatrie1990;47(6):461-5. [PMID: 2206108]BairamA , BoutroyMJ , BadonnelY , VertP . Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. Journal of Pediatrics1987;110(4):636-9. [DOI: 10.1016/s0022-3476(87)80569-3] [PMID: 3559816]">Bairam 1987</a>; <a href="./references#CD015462-bbs2-0002" title="BrouardC , MorietteG , MuratI , FlouvatB , PajotN , WaltiH , et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. American Journal of Diseases of Children1985;139(7):698-700. [DOI: 10.1001/archpedi.1985.02140090060028] [PMID: 4014092]">Brouard 1985</a>). Previous research on adverse effects indicates that theophylline and aminophylline are associated with more adverse effects compared to caffeine. In our review, we only looked at adverse effects leading to a reduction in dose. For this outcome, we had a total of six events, which was too few to draw any conclusions. If we had chosen to look at all adverse effects, it is possible the results would have been different. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015462-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD015462-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#CD015462-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD015462-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#CD015462-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD015462-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#CD015462-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 1: All‐cause mortality prior to hospital discharge" data-id="CD015462-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 1: All‐cause mortality prior to hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 2: Moderate to severe neurodevelopmental disability at 18 to 26 months ‐ developmental delay more than two SDs below population mean on a standardized test of development: cognitive" data-id="CD015462-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 2: Moderate to severe neurodevelopmental disability at 18 to 26 months ‐ developmental delay more than two SDs below population mean on a standardized test of development: cognitive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 3: Moderate to severe neurodevelopmental disability at 18 to 26 months ‐ developmental delay more than two SDs below population mean on a standardized test of development: language" data-id="CD015462-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 3: Moderate to severe neurodevelopmental disability at 18 to 26 months ‐ developmental delay more than two SDs below population mean on a standardized test of development: language </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 4: Moderate to severe neurodevelopmental disability at 18 to 26 months ‐ developmental delay more than two SDs below population mean on a standardized test of development: motor" data-id="CD015462-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 4: Moderate to severe neurodevelopmental disability at 18 to 26 months ‐ developmental delay more than two SDs below population mean on a standardized test of development: motor </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 5: Bronchopulmonary dysplasia/chronic lung disease: defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age" data-id="CD015462-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 5: Bronchopulmonary dysplasia/chronic lung disease: defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 6: Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines" data-id="CD015462-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 6: Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 7: Failure to extubate within one week of commencing treatment" data-id="CD015462-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 7: Failure to extubate within one week of commencing treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 8: Failed apnea reduction after two to seven days (less than 50% reduction in apnea), for infants treated for apnea" data-id="CD015462-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 8: Failed apnea reduction after two to seven days (less than 50% reduction in apnea), for infants treated for apnea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 9: Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after 24 hours from commencing treatment over a 24‐hour period" data-id="CD015462-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 9: Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after 24 hours from commencing treatment over a 24‐hour period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 10: Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after one week" data-id="CD015462-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 10: Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after one week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 11: Apnea: number of infants with at least one episode (defined as interruption of breathing for more than 20 seconds) after 24 hours of commencing treatment after one week" data-id="CD015462-fig-0014" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 11: Apnea: number of infants with at least one episode (defined as interruption of breathing for more than 20 seconds) after 24 hours of commencing treatment after one week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 12: Number of days of respiratory support (mechanical ventilation; continuous positive airway pressure [CPAP]; high‐flow nasal cannula; non‐invasive positive‐pressure ventilation [NIPPV])" data-id="CD015462-fig-0015" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 12: Number of days of respiratory support (mechanical ventilation; continuous positive airway pressure [CPAP]; high‐flow nasal cannula; non‐invasive positive‐pressure ventilation [NIPPV]) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 13: Number of days of supplemental oxygen" data-id="CD015462-fig-0016" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 13: Number of days of supplemental oxygen </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 14: Intraventricular hemorrhage on brain ultrasound (any; and severe [Papile grade 3 to 4])" data-id="CD015462-fig-0017" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 14: Intraventricular hemorrhage on brain ultrasound (any; and severe [Papile grade 3 to 4]) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 15: Periventricular leukomalacia" data-id="CD015462-fig-0018" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 15: Periventricular leukomalacia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 16: Necrotizing enterocolitis (proven = Bell stage 2 or greater)" data-id="CD015462-fig-0019" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 16: Necrotizing enterocolitis (proven = Bell stage 2 or greater) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 17: Patent ductus arteriosus (PDA) requiring treatment (cyclo‐oxygenase inhibitors or surgical ligation)" data-id="CD015462-fig-0020" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 17: Patent ductus arteriosus (PDA) requiring treatment (cyclo‐oxygenase inhibitors or surgical ligation) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015462-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/urn:x-wiley:14651858:media:CD015462:CD015462-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Caffeine versus other methylxanthines, Outcome 18: Retinopathy of prematurity (ROP) (any ROP; and severe ROP [stage 3 or greater])" data-id="CD015462-fig-0021" src="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_t/tCD015462-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Caffeine versus other methylxanthines, Outcome 18: Retinopathy of prematurity (ROP) (any ROP; and severe ROP [stage 3 or greater]) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/media/CDSR/CD015462/image_n/nCD015462-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015462-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Caffeine compared to other methylxanthines for the prevention and treatment of apnea in preterm infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Caffeine compared to other methylxanthines for the prevention and treatment of apnea in preterm infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> preterm infants <br/><b>Setting:</b> neonatal intensive care units<br/><b>Intervention:</b> caffeine <br/><b>Comparison:</b> other methylxanthines </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Without caffeine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With caffeine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality prior to hospital discharge</b> <br/><b>№ of participants:</b> 396<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/>(0.68 to 1.84) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caffeine may result in little to no difference in all‐cause mortality prior to hospital discharge compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.1%<br/>(8.6 to 23.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5% more<br/>(4 fewer to 10.6 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate to severe neurodevelopmental disability at 18 to 26 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>No studies reported this composite outcome. Components of this outcome are reported below. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a) Cerebral palsy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>b) Gross motor disability defined as ≥ level 2 according to the GMFCS</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>c) Developmental delay more than two SDs below population mean on a standardized test of development: cognitive delay </p> <p>№ of participants: 79<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.17<br/>(0.02 to 1.37) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of caffeine on cognitive developmental delay compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4% (0.3 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5% fewer (13.6 fewer to 5.1 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>c) Developmental delay more than two SDs below population mean on a standardized test of development: language delay </p> <p>№ of participants: 79<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.76 (0.37 to 1.58)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of caffeine on language developmental delay compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.2% (11.3 to 48.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.4% fewer (28.3 fewer to 8.7 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>c) Developmental delay more than two SDs below population mean on a standardized test of development: motor delay </p> <p>№ of participants: 79<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.50 (0.13 to 1.96)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of caffeine on motor developmental delay compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9% (1.8 to 27.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7% fewer (12.1 fewer to 13.3 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d) Mental development IQ &gt; 2 SD below the mean</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>e) Visual impairment (vision &lt; 6/60 in both eyes)</p> <p>№ of participants: 21<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>This outcome was reported only for those infants with ROP diagnosis at discharge. Visual impairment was seen in 8 out of 11 and 10 out of 11 infants in the caffeine and other methylxanthines groups, respectively. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of caffeine on visual impairment compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>f) Hearing impairment (requiring amplification)</p> <p>№ of participants: 6<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>This outcome was reported only for those infants with abnormal hearing screening prior to discharge using ABR and OAE. Hearing impairment was seen in 2 out of 5 infants and 1 out of 1 infant in the caffeine and other methylxanthines groups, respectively. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of caffeine on hearing impairment compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Bronchopulmonary dysplasia/chronic lung disease: defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age</b> <br/><b>№ of participants:</b> 481<br/>(3 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/>(0.92 to 2.11) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caffeine may result in little to no difference in bronchopulmonary dysplasia/chronic lung disease (defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age) compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.5%<br/>(8.9 to 20.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9% more<br/>(0.8 fewer to 10.7 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines</b> <br/><b>№ of participants:</b> 30<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.17<br/>(0.02 to 1.32) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of caffeine on side effects ((tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines) compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1%<br/>(0.7 to 47.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.6% fewer<br/>(35 fewer to 11.4 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of hospital stay (days)</b> </p> <p><b>№ of participants:</b> 240 </p> <p>(1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>One study reported this outcome with median and IQR and therefore could not be pooled in the meta‐analysis: caffeine 43 days (IQR 27.5 to 61.5); other methylxanthines: 39 (IQR 28 to 55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caffeine may result in little to no difference in duration of hospital stay compared to other methylxanthines. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizures (clinically diagnosed)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>ABR:</b> auditory brainstem evoked response; <b>CI:</b> confidence interval; <b>GMFCS</b> : Gross Motor Function Classification System; <b>IQ:</b> intelligence quotient; <b>IQR</b> : interquartile range; <b>OAE</b> : otoacoustic emission; <b>RCT:</b> randomized controlled trial; <b>ROP</b> : retinopathy of prematurity; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision: very wide CIs<br/><sup>b</sup>Downgraded one level for serious study limitations: multiple domains of the risk of bias unclear or high<br/><sup>c</sup>Downgraded two levels for very serious imprecision: one study with wide CIs<br/><sup>d</sup>Downgraded two levels for very serious imprecision: one study with very few infants and events<br/><sup>e</sup>Downgraded one level for serious imprecision: three studies, wide CIs<br/><sup>f</sup>Downgraded three levels for extremely serious imprecision: very wide CI; few infants and events<br/><sup>g</sup>Downgraded two levels for very serious imprecision: one study with wide interquartile ranges </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Caffeine compared to other methylxanthines for the prevention and treatment of apnea in preterm infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/full#CD015462-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015462-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Caffeine versus other methylxanthines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality prior to hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.68, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Moderate to severe neurodevelopmental disability at 18 to 26 months ‐ developmental delay more than two SDs below population mean on a standardized test of development: cognitive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.02, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Moderate to severe neurodevelopmental disability at 18 to 26 months ‐ developmental delay more than two SDs below population mean on a standardized test of development: language <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.37, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Moderate to severe neurodevelopmental disability at 18 to 26 months ‐ developmental delay more than two SDs below population mean on a standardized test of development: motor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.13, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Bronchopulmonary dysplasia/chronic lung disease: defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.92, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.02, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Failure to extubate within one week of commencing treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.14, 3.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Failed apnea reduction after two to seven days (less than 50% reduction in apnea), for infants treated for apnea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [0.50, 9.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after 24 hours from commencing treatment over a 24‐hour period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐0.76, ‐0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after one week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.14, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Apnea: number of infants with at least one episode (defined as interruption of breathing for more than 20 seconds) after 24 hours of commencing treatment after one week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.83, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Number of days of respiratory support (mechanical ventilation; continuous positive airway pressure [CPAP]; high‐flow nasal cannula; non‐invasive positive‐pressure ventilation [NIPPV]) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐1.81, ‐0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Number of days of supplemental oxygen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.15 [‐1.81, ‐0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Intraventricular hemorrhage on brain ultrasound (any; and severe [Papile grade 3 to 4]) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.30, 3.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.11, 3.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Necrotizing enterocolitis (proven = Bell stage 2 or greater) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.09, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Patent ductus arteriosus (PDA) requiring treatment (cyclo‐oxygenase inhibitors or surgical ligation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.46, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Retinopathy of prematurity (ROP) (any ROP; and severe ROP [stage 3 or greater]) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.42, 3.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Caffeine versus other methylxanthines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015462.pub2/references#CD015462-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015462.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD015462-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015462-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015462-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD015462-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD015462-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD015462-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD015462-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015462-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015462-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015462\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015462\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015462\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015462\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015462\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015462.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015462.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015462.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015462.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015462.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714210129"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015462.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714210133"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015462.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6919dd9df3cd',t:'MTc0MDcxNDIxMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 